Derivatives of 3-aminopropane-1,2-diol

ABSTRACT

Derivatives of 3-aminopropane-1,2-diol of the formula ##STR1## in which Ar represents optionally substituted aryl, 
     n represents the number 0 or 1, and 
     alk represents alkylene having 2 to 5 carbon atoms, the nitrogen atom and the oxygen atom, or, if n is zero, the phenyl radical, being separated from one another by at least two carbon atoms, and 
     R 1  and R 2 , independently of one another, each represents hydrogen or lower alkyl, or together they represent lower alkylene, oxa-lower alkylene, thia-lower alkylene, aza-lower alkylene or N-lower alkyl-aza-lower alkylene, 
     and salts of such compounds, processes for their manufacture, medicaments containing the new compounds and their use for the treatment of Angina pectoris and cardiac arrhythmia, and as blood pressure-reducing agents, as well as for the treatment of reactive or endogenic states of depression.

This is a continuation-in-part of our copending application Ser. No.255,424 filed Apr. 20, 1981, now abandoned which in turn is acontinuation-in-part of our application Ser. No. 181,581, filed Aug. 27,1980, now abandoned, which in turn is a continuation-in-part of ourapplication Ser. No. 122,640, filed Feb. 19, 1980, now abandoned.

The invention relates to new derivatives of 3-aminopropane-1,2-diol,processes for their preparation, pharmaceutical preparations containingsuch compounds and their use for the manufacture of pharmaceuticalpreparations or as pharmacologically active compounds.

The new derivatives of 3-aminopropane-1,2-diol according to theinvention corresponds to the formula ##STR2## in which

Ar represents optionally substituted aryl,

n represents the integer 0 or 1, and

alk represents alkylene having from 2 to 5 carbon atoms, the nitrogenatom and the oxygen atom, or if n is zero, the phenyl radical, beingseparated from one another by at least two carbon atoms, and

R₁ and R₂, independently of one another, each represents hydrogen orlower alkyl, or together they represent lower alkylene, oxa-loweralkylene, thia-lower alkylene, aza-lower alkylene or N-loweralkyl-aza-lower alkylene.

The invention also relates to salts of these compounds.

An aryl radical Ar is a carbocyclic or heterocyclic aryl radical.Preferably, Ar is monocyclic or bicyclic carbocyclic aryl or monocyclicor bicyclic heteroaryl bonded by a ring carbon atom and containing asring members a maximum of two nitrogen atoms and/or one oxygen orsulphur atom. These radicals may be unsubstituted or substituted one ormore times, preferably at most three times, and in bicyclic radicals Ar,the ring not directly bonded to the ether group may be at leastpartially hydrogenated and in this case may be substituted especially byoxo. Ar is especially phenyl, or also naphthyl, such as 1-naphthyl, orpartially saturated naphthyl, such as 1,2,3,4-tetrahydro-5-naphthyl;when Ar represents monocyclic or bicyclic heteroaryl it is especiallypyridyl, for example, pyrid-2-yl, pyrid-3-yl or pyrid-4-yl, pyridazinyl,for example pyridazin-3-yl, pyrimidinyl, for example pyrimidin-2-yl orpyrimidin-4-yl, pyrazinyl, e.g. pyrazin-2-yl, thienyl, for examplethien-3-yl, thiazolyl, e.g. thiazol-2-yl, thiadiazolyl, e.g.1,2,4-thiadiazol-3-yl or -5-yl or 1,2,5-thiadiazol-3-yl, ndolyl, e.g.indol-4-yl, quinolinyl, e.g. quinolin-2-yl, isoquinolinyl, e.g.isoquinolin-1-yl, 2-oxobenzimidazol-4-yl, naphthyridinyl, e.g.1,8-naphthyridin-2-yl, or benzofuranyl, for example benzofuran-4-yl orbenzofuran-5-yl.

Possible substituents of radicals Ar, for example of the radicalsdefined in detail above and of the radicals mentioned hereinbefore asexamples, are, for example, optionally substituted, especially in themanner specified hereinafter, lower alkyl, lower alkenyl or loweralkoxy, also lower alkenyloxy, lower alkynyl, lower alkynyloxy, cyanoand/or nitro, and/or, as substituents bonded directly or to theabove-mentioned lower alkyl, lower alkenyl or lower alkoxy, one or moreof lower alkanoyl, cycloalkyl, esterified or amidated carboxyl,especially lower alkoxycarbonyl or optionally substituted carbamoyl, forexample carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl or(hydroxy-lower alkyl) carbamoyl, lower alkylsulphinyl, loweralkylsulphonyl, sulphamoyl or lower alkylsulphamoyl; or halogen bondeddirectly or halogen bonded to the above-mentioned lower alkyl or, in aposition higher than the 1-position, halogen bonded to theabove-mentioned lower alkoxy; or optionally etherified or esterifiedhydroxy, such as hydroxy, bonded directly or bonded to the abovementioned lower alkyl such as hydroxy-lower alkyl or polyhydroxy-loweralkyl, substituents not directly bonded are, again, lower alkoxy,cycloalkyl-lower alkoxy, also phenyl-lower alkoxy, or lower alkanoyloxy,etherified mercapto, such as lower alkylthio, optionally substitutedamino, such as amino, lower alkylamino, di-lower alkylamino,alkyleneamino or oxa-alkyleneamino, pyrrol-1-yl, acylamino, such aslower alkanoylamino, lower alkoxycarbonylamino, optionally substitutedureido, especially ureido substituted by one or two lower alkylradicals, by hydroxy-lower alkyl or by cycloalkyl, loweralkylsulphonylamino or N-lower alkyl lower alkylsulphonylamino.

The radicals and compounds denoted by "lower" in connection with thepresent description contain preferably up to 7, and especially up to 4,carbon atoms.

The general terms used in the enumeration of substituents of the radicalAr may have, for example, the following specific meanings. Lower alkylis, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,or tert.-butyl; substituted lower alkyl is especially correspondingmethyl or 1- or 2-substituted ethyl. Lower alkenyl is, for example,vinyl, allyl, 2- or 3-methallyl or 3,3-dimethallyl, and substitutedlower alkenyl is especially 2-substituted vinyl or 3-substituted allyl.Cycloalkyl has from 3 to 7 ring members and is for example, cyclopropyl.Lower alkoxy is, for example, methoxy, ethoxy, n-propoxy, isopropoxy,n-butoxy or isobutoxy, and substituted lower alkoxy is, for example,substituted methoxy or 1- or 2-substituted ethoxy. Lower alkenyloxy is,for example, allyloxy, 2- or 3-methallyloxy or 3,3-dimethallyloxy. Loweralkynyl is, for example, propargyl, and lower alkynyloxy is especiallypropargyloxy. Lower alkanoyl is, for example, acetyl, propionyl orbutyryl. Lower alkoxycarbonyl is, for example, methoxycarbonyl orethoxycarbonyl. Lower alkylcarbamoyl or di-lower alkylcarbamoyl is, forexample, methylcarbamoyl, dimethylcarbamoyl ethylcarbamoyl ordiethylcarbamoyl, and hydroxy-lower alkylcarbamoyl is, for example,(2-hydroxyethyl)carbamoyl. Lower alkylsulphinyl is, for example, methyl-or ethylsulphinyl, lower alkylsulphonyl is, for example, methyl-, ethyl-or propylsulphonyl, and lower alkylsulphamoyl is, for example, methyl-,ethyl- or isopropylsulphamoyl. Halogen may be bromine or iodine, but ispreferably fluorine or chlorine. Cycloalkyl-lower alkoxy is for examplecyclopropylmethoxy or 1- or 2-cyclopropylethoxy. Phenyl-lower alkoxy is,for example, benzyloxy or 1- or 2-phenylethoxy, and lower alkanoyloxyis, for example, formyloxy, acetoxy, propionyloxy, butyryloxy orisobutyryloxy. Lower alkylthio is, for example, methylthio, n-propylthioor isopropylthio. Lower alkylamino and di-lower alkylamino are, forexample, methylamino, ethylamino, dimethylamino or diethylamino.Alkyleneamino and oxa-alkyleneamino are, e.g., pyrrolidino, piperidinoor morpholino. Lower alkanoylamino is, for example, acetylamino orbutyrylamino, and lower alkoxycarbonylamino is, for example,methoxycarbonylamino or ethoxycarbonylamino. Ureido substituted by oneor two lower alkyl radicals, by hydroxy-lower alkyl or by cycloalkylpreferably having 5 to 7 ring members, is e.g. 3-methylureido,3,3-dimethylureido, 3-(2-hydroxyethyl)ureido, or 3-cyclohexylureido.Lower alkylsulphonylamino is e.g. ethylsulphonylamino and especiallymethylsulphonylamino, N-lower alkyl lower alkylsulphonylamino is e.g.N-methyl methylsulphonylamino.

As stated above, substituents of Ar may be one of the above-mentionedradicals which is bonded not directly but through lower alkyl, loweralkoxy or optionally also through lower alkenyl. General and specificexamples of such substituents are given in the following but thepossible combinations are not limited thereto. Lower alkanoylalkyl ise.g. 2-oxopropyl (acetonyl) or 3-oxobutyl; lower alkanoyl-lower alkenylis e.g. 3-oxobut-1-enyl, and lower alkanoylalkoxy is e.g. 2-oxopropoxy(acetonyloxy) or 3-oxobutoxy. Optionally substituted carbamoyl-loweralkyl is e.g. carbamoylmethyl or [(hydroxy-lower alkyl)carbamoyl)]-loweralkyl, such as [(2-hydroxyethyl)carbamoyl)]methyl. Loweralkoxycarbonyl-lower alkoxy is e.g. ethoxycarbonylmethoxy. Optionallysubstituted carbamoyl-lower alkoxy is, for example, carbamoyl-loweralkoxy, such as carbamoylmethoxy, or [(hydroxy-loweralkyl)carbamoyl]lower alkoxy, such as[(2-hydroxyethyl)carbamoyl]methoxy. Halo-lower alkyl is especiallyhalomethyl, e.g. trifluoromethyl. Hydroxy-lower alkyl is preferablyhydroxymethyl, or 1- or especially 2-hydroxyethyl. Polyhydroxy-loweralkyl is, for example, di- or trihydroxy-lower alkyl such as1,2-dihydroxy- or 2,3-dihydroxy-lower alkyl for example 1,2-dihydroxy-or 2,3-dihydroxypropyl. Lower alkoxy-lower alkyl is preferably loweralkoxymethyl or 1- or especially 2-lower alkoxyethyl, e.g.methoxymethyl, ethoxymethyl, 2-methoxyethyl or 2-ethoxyethyl.Cycloalkyl- lower alkoxy-lower alkyl is preferably cycloalkyl-loweralkoxy methyl or 1- or 2-(cycloalkyl-lower alkoxy)-ethyl e.g. 1- or2-(cyclopropylmethoxy)-ethyl. Lower alkoxy-lower alkoxy is especially2-lower alkoxyethoxy, such as 2-methoxyethoxy or 2-ethoxyethoxy; loweralkylthio-lower alkoxy is e.g. 2-methylthioethoxy or 2-ethylthioethoxy.Acylamino-lower alkyl is e.g. lower alkanoylamino-lower alkyl,especially lower alkanoylaminomethyl, or 1- or especially 2-loweralkanoylaminoethyl, e.g. acetylaminomethyl, 2-acetylaminoethyl or2-propionylaminoethyl; or lower alkoxycarbonylamino-lower alkyl,especially lower alkoxycarbonylaminomethyl, or 1- or especially 2-loweralkoxycarbonylaminoethyl e.g. methoxycarbonylaminomethyl,2-methoxycarbonylaminoethyl or 2-ethoxycarbonylaminoethyl.Acylamino-lower alkoxy is e.g. lower alkanoylamino-lower alkoxy,especially 2-lower alkanoylaminoethoxy, e.g. 2-(acetylamino)ethoxy, orlower alkoxycarbonylamino-lower alkoxy, especially 2-(loweralkoxycarbonylamino)ethoxy, e.g. 2-(methoxycarbonylamino)ethoxy or2-(ethoxycarbonylamino)ethoxy. Lower alkylcarbamoyl lower alkenyl is,for example, N-methylcarbamoyl lower alkenyl such as N-methylcarbamoylvinyl.

Alkylene alk may be straight chain or branched and is, for example,ethylene, trimethylene, propylene, tetramethylene, 1-methyltrimethylene,1,1-dimethyltrimethylene or 1,1-dimethylethylene.

R₁ and R₂ having the meaning lower alkyl are, for example, propyl,isopropyl, butyl, isobutyl, sec.-butyl, pentyl, isopentyl, neopentyl,hexyl or heptyl, and especially methyl or ethyl. Together with thenitrogen atom of the amide group, R₁ and R₂ as lower alkylene are, forexample, aziridin-1-yl, azetidin-1-yl, pyrrolidino, piperidino,hexahydro-1H-azepin-1-yl; as oxa-lower alkylene e.g. morpholino; asthia-lower alkylene e.g. thiomorpholino; as aza-lower alkylene e.g.piperazin-1-yl or hexahydro-1H-1,4-diazepin-1-yl, wherein the twolast-mentioned groups, corresponding to the meaning N-loweralkyl-aza-lower alkylene for R₁ and R₂ in the 4-position, that is in theimino group, may be substituted, for example, by lower alkyl, such asmethyl, ethyl, propyl, isopropyl, butyl or isobutyl.

The phenyl radical carrying the amide and the hydroxy group may bebonded in any position to the remainder of the molecule; preferably, thelatter is bonded in the 4-position of the said phenyl radical, that is,in the position para to the amide group, and is bonded especially in the5-position of the said phenyl radical, (that is, in the position para tothe hydroxy group).

The new compounds may exist in the form of their salts, such as theiracid addition salts, and especially in the form of theirpharmaceutically acceptable, non-toxic acid addition salts. Suitablesalts are e.g. those with inorganic acids, such as hydrohalic acids,e.g. hydrochloric acid or hydrobromic acid, sulphuric acid or phosphoricacid, or with organic acids, such as aliphatic, cycloaliphatic, aromaticor heterocyclic carboxylic or sulphonic acids, e.g. formic, acetic,propionic, succinic, glycolic, lactic, malic, tartaric, citric, maleic,hydroxymaleic, pyruvic, fumaric, benzoic, 4-aminobenzoic, anthranilic,4-hydroxybenzoic, salicyclic, embonic, methanesulphonic,ethanesulphonic, 2-hydroxyethanesulphonic, ethylenesulphonic,toluenesulphonic, naphthalenesulphonic or sulphanilic acids, or withother acidic organic substances, such as ascorbic acid.

The new compounds have valuable pharmacological properties. Inparticular, they act in a specific manner on β-adrenergic receptors.This action is attributed to the affinity for these receptors, which isa property common to the compounds of the formula I. With no or onlyvery slight inherent stimulating action this affinity is reflected as apure blocking, and with slight to moderate inherent stimulating actionis reflected as a blocking with simultaneous ISA (i.e. intrinsicsympathomimetic activity), and, with relatively strong inherent action,as actual stimulation of the β-adrenergic receptors. Pronouncedβ-receptor-stimulating and at the same time cardioselective activity isfound especially with those compounds of formula I in which Arrepresents a hydroxyphenyl radical. Of the remaining compounds of theformula I, the β-receptor-blockers with or without ISA, those having asubstituent in the p-position, such as especially1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,exhibit a more or less pronounced cardioselectivity. This action is lessclear, or lacking, however, in compounds with ortho-substitution in thebroadest sense, that is, the presence of a single substituent or a fusedring in the position ortho to the ether group. On the other hand, suchcompounds in addition have α-receptor blocking properties. An example ofsuch a compound is especially1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-ol.

The above details referring to pharmacological properties are based onthe results of appropriate pharmacological experiments in conventionaltest methods. Thus, in a concentration range of from approximately 0.001μg/ml to approximately 1 μg/ml the new β-blocking compounds inhibittachycardia induced by isoproterenol in isolated guinea pig hearts andin a dosage range of from approximately 0.001 mg/kg to approximately 3mg/kg, they inhibit the same condition in anaesthetised cats whenadministered intravenously. In the same dosage range, in anaesthetisedcats the β-blocking compounds of the formula I also inhibit an increasein heart rate induced by electrical stimulation of the sympatheticnerves. The inhibition of vasodilation induced by isoproterenol inanaesthetised cats with perfusion of the arteria femoralis can bedemonstrated with cardioselective compounds of the formula I whenadministered intravenously in a dosage range of from approximately 0.1mg/kg to approximately 30 mg/kg, and with non-cardioselective compoundsin a dosage range of from 0.001 to 1 mg/kg. The ISA of the β-blockingcompounds of the formula I is shown by the increase in the basal heartrate in anaesthetised cats previously treated with reserpine, when thecompounds are administered intravenously in a dosage range of from 0.001to 1 mg/kg. The new β-blocking compounds also cause a reduction inarterial blood pressure of anaesthetised cats in a dosage range of fromapproxmately 0.01 mg/kg to approximately 10 mg/kg i.v. The additionalα-blocking activity of the non-cardioselective β-receptor-blockers whichmay, for example, promote a blood pressure-reducing action, is shown,for example, in the antagonisation of the noradrenalin-inducedcontraction of the isolated vas deferens of rats by such compounds in aconcentration of from 0.01-3 μg/ml. The new β-blocking compounds of theformula I may be used as optionally cardioselective β-receptor-blockers,for example for the treatment of angina pectoris and cardiac arrhythmia,and as blood pressure-reducing agents.

The β-stimulating compounds of the formula I, such as1-(4-hydroxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]propan-2-ol,for example that racemate of which the neutral fumarate melts at195°-198°, cause an increase in heart rate and myocardial contractionforce in the isolated guinea pig auricle in a concentration range offrom approximately 0.0001 to 0.1 μg/ml, and cause an increase in heartrate and maximum pressure increase speed in the left ventricle (dp/dtmax), in anaesthetised cats in a dosage range of from approximately0.0001 to approximately 0.1 mg/kg i.v. On the other hand, higher doses,corresponding to a dosage range of from approximately 0.001 toapproximately 1 mg/kg i.v., are required to reduce arterial bloodpressure in anaesthetised cats, that is to say, the new compoundsstimulate specifically the cardial β-receptors (β₁ -receptors) comparedwith the β-receptors in the blood vessels (β₂ -receptors) and arethereby qualitatively clearly distinguished from isoproterenol whichstimulates the β-receptors of the heart and the blood vesselsapproximately equally strongly. The new compounds may therefore be usedas positively inotropically acting agents, especially as cardiotonicagents for the treatment of myocardial insufficiency, either alone or incombination with other preparations, such as cardiac glycosides, andalso for the treatment of certain disturbances in cardiac rhythm.

Compounds of the formula I, in which Ar is phenyl unsubstituted orsubstituted one to three times by hydroxy exhibit effects on the centralnervous system, which are reflected for example in the suppression ofthe symptoms of impaired sympathetic functions and in the suppression oflack of initiative, as can be demonstrated for example by virtue of theantagonism against hypothermia induced in mice after s.c.-administrationof 2 mg/kg of reserpine (B. Benz et al,: Arzneimittelforschung 21,654-61 (1971)) in a dose of about 3 mg/kg to about 100 mg/kg i.p., or byvirtue of the antagonism against hypothermia induced in mice afters.c.-administration of 10 mg/kg of apomorphine (Puech A. L.: Europ. J.of Pharmacol. 47, 127-27 (1978); Schelkunov E. L.: Psychopharmacol. 55,87-95 (1977)) in a dose range of about 0,03 mg/kg to about 1 mg/kg i.p.,or by virtue of the antagonism against hypothermia induced in mice afteri.p.-administration of 0,25 mg/kg of clonidine (Voigtlaender P. F. etal,: Neuropharmacol. 17, 375-81 (1978)) in a dose range of about 0,01mg/kg to about 0,3 mg/kg i.p. With respect to these results suchcompounds of the formula I can be used for the treatment of reactive orendogenic states of depression of varying degrees of severity, and alsofor the treatment of neurotic or other psychic disturbances involvingloss of initiative and depressive disorders. Such compounds can also beused for the short-term treatment of post-partum or postoperativedepression, or of depression of different origin. Such compounds of theformula I can be used on their own or in combination with otherantidepressants.

The compounds of the general formula I may also be used as valuableintermediates for the preparation of other more valuable compounds,especially compounds that are pharmaceutically more effective.

The invention relates in particular to compounds of the formula I inwhich Ar represents monocyclic or bicyclic carbocyclic aryl ormonocyclic or bicyclic heteroaryl bonded by a ring carbon atom andcontaining as ring members a maximum of two nitrogen atoms and/or oneoxygen or sulphur atom, which radicals may be unsubstituted orsubstituted one or more times, preferably at most three times, whereinas substituents there may be present optionally substituted, especiallyin the manner specified hereinafter, lower alkyl, lower alkenyl or loweralkoxy, also lower alkenyloxy, lower alkynyl, lower alkynyloxy, cyanoand/or nitro, and/or, as substituents bonded directly or to theabove-mentioned lower alkyl, lower alkenyl or lower alkoxy, one or moreof lower alkanoyl, cycloalkyl, esterified or amidated carboxyl,especially lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl or(hydroxy-lower alkyl)carbamoyl, lower alkylsulphinyl, loweralkylsulphonyl, sulphamoyl or lower alkylsulphamoyl; and/or, halogenbonded directly or halogen bonded to the above-mentioned lower alkyl or,in a position higher than the 1-position, halogen bonded to theabove-mentioned lower alkoxy; optionally etherified or esterifiedhydroxy, such as hydroxy bonded directly or bonded to theabove-mentioned lower alkyl or, as substituent not directly bonded,again lower alkoxy, cycloalkyl-lower alkoxy, also phenyl-lower alkoxy,for example benzyloxy, or lower alkenyloxy, etherified mercapto, such aslower alkylthio, optionally substituted amino, such as amino, loweralkylamino, di-lower alkylamino, alkyleneamino or oxaalkyleneamino, forexample, pyrrolidino, piperidino or morpholino, pyrrol-1-yl, acylamino,such as lower alkanoylamino, lower alkoxycarbonylamino, ureidooptionallyl substituted by lower alkyl, by hydroxy-lower alkyl or bycycloalkyl, lower alkylsulphonylamino or N-lower alkyl loweralkylsulphonylamino, and in bicyclic radicals Ar, the ring not directlybonded to the ether group is also at least partially hydrogenated and inthis case may also be substituted by oxo; and in which n is the number 0or 1, alk is an alkylene radical having from 2 to 4 carbon atoms, thenitrogen atom and the oxygen atom or, if n is 0, the phenyl radical,being separated from one another by 2 or 3 carbon atoms, and R₁ and R₂have the meanings given under formula I but preferably representhydrogen or lower alkyl, for example methyl or ethyl, or together withthe nitrogen atom of the amide group, form morpholino or alkyleneaminohaving 5 or 6 ring members, such as pyrrolidino or piperidino; and saltsthereof, especially acid addition salts, more especiallypharmaceutically acceptable non-toxic acid addition salts.

The invention relates preferably to compounds of the formula I in whichAr represents monocyclic or bicyclic carbocyclic aryl or monocyclic orbicyclic heteroaryl bonded by a ring carbon atom and containing as ringmembers a maximum of two nitrogen atoms and/or one oxygen or sulphuratom, which radicals may be unsubstituted or substituted one to threetimes, wherein as substituents there may be present, optionallysubstituted in the manner specified hereinafter, lower alkyl, loweralkenyl or lower alkoxy, also lower alkenyloxy, lower alkynyl, loweralkynyloxy, cyano and/or nitro, and/or, as substituents bonded directlyor to the above-mentioned lower alkyl, lower alkenyl or lower alkoxy,one or more of lower alkanoyl, cycloalkyl, lower alkoxycarbonyl,carbamoyl, lower alkylcarbamoyl or (hydroxy-lower alkyl)-carbamoyl,lower alkylsulphinyl, lower alkylsulphonyl, sulphamoyl or loweralkylsulphamoyl; and/or halogen bonded directly or halogen bonded to theabove-mentioned lower alkyl or, in a position higher than the1-position, halogen bonded to the above-mentioned lower alkoxy; hydroxy,hydroxy-lower alkyl or polyhydroxy-lower alkyl, or, as substituent notdirectly bonded, again lower alkoxy, cycloalkyl-lower alkoxyphenyl-lower alkoxy, for example benzyloxy, lower alkanoyloxy, loweralkylthio, amino, lower alkylamino, di-lower alkylamino, alkyleneaminoor oxaalkyleneamino, for example pyrrolidino, piperidino or morpholino,pyrrol-1-yl, lower alkanoylamino or lower alkoxycarbonylamino, ureidooptionally substituted by lower alkyl, by hydroxy-lower alkyl or bycycloalkyl, lower alkylsulphonylamino or N-lower alkyl loweralkylsulphonylamino, and, in bicyclic radicals Ar, the ring not directlybonded to the ether group is also at least partially hydrogenated and inthis case may also be substituted by oxo; and in which n represents thenumber 0 or 1, alk represents an alkylene radical having from 2 to 4carbon atoms, the nitrogen atom and the oxygen atom or, if n is 0, thephenyl radical, being separated from one another by 2 or 3 carbon atoms,and R₁ and R₂ have the meanings given under formula I but preferablyrepresent hydrogen or lower alkyl, especially methyl or ethyl, or,together with the nitrogen atom of the amide group, form pyrrolidino,piperidino or morpholino; and salts thereof, especially acid additionsalts, more especially pharmaceutically acceptable, non-toxic acidaddition salts.

The invention relates especially to compounds of the formula I in whichAr represents phenyl, naphthyl or 1,2,3,4-tetrahydro-5-naphthyl, whichradicals may be unsubstituted or substituted one to three times, whereinas substituents there may be present, optionally substituted in themanner specified hereinafter, lower alkyl, lower alkenyl or loweralkoxy, also lower alkenyloxy, lower alkynyloxy, and/or cyano, and/or,as substituents bonded directly or to the above-mentioned lower alkyl,lower alkenyl or lower alkoxy, one or more of lower alkanoyl, loweralkoxycarbonyl, cycloalkyl, carbamoyl, lower alkylcarbamoyl or(hydroxy-lower alkyl)carbamoyl, lower alkylsulphinyl, loweralkylsulphonyl, sulphamoyl or lower alkylsulphamoyl; and/or halogenbonded directly or halogen bonded to the above-mentioned lower alkyl or,in a position higher than the 1-position, halogen bonded to theabove-mentioned lower alkoxy; hydroxy, hydroxy-lower alkyl orpolyhydroxy-lower alkyl, or, as substituent not directly bonded, againlower alkoxy, cycloalkyl-lower alkoxy, also phenoxy-lower alkoxy, forexample benzyloxy, lower alkanoyloxy, lower alkylthio, amino, loweralkylamino, di-lower alkylamino, alkyleneamino or oxa-alkyleneamino, forexample pyrrolidino, piperidino or morpholino, pyrrol-1-yl, loweralkanoylamino or lower alkoxycarbonylamino, ureido optionallysubstituted by lower alkyl or cycloalkyl, lower alkylsulphonylamino orN-lower alkyl lower alkylsulphonylamino, and in which n represents thenumber 0 or 1, alk represents an alkylene radical having from 2 to 4carbon atoms, the nitrogen atom and the oxygen atom or, if n is 0, thephenyl radical, being separated from one other by 2 or 3 carbon atoms,and R₁ and R₂, independently of one another, each represents hydrogen orlower alkyl, especially methyl or ethyl, or, together with the nitrogenatom of the amide group, form morpholino; and salts thereof, especiallyacid addition salts, more especially pharmaceutically acceptablenon-toxic acid addition salts.

The invention relates especially to compounds of the formula I in whichAr represents phenyl which may be unsubstituted or substituted one tothree times, wherein as substituents there may be present, optionallysubstituted in the manner specified hereinafter, lower alkyl or loweralkoxy, also lower alkenyl, lower alkenyloxy, lower alkynyloxy, and/orcyano, and/or, as substituents bonded directly or to the above-mentionedlower alkyl, lower alkoxy or lower alkenyl, one or more of loweralkanoyl, cycloalkyl, lower alkoxycarbonyl, carbamoyl, loweralkylcarbamoyl or (hydroxy-lower alkyl)carbamoyl, lower alkylsulphinylor lower alkylsulphonyl; and/or halogen bonded directly or halogenbonded to the above-mentioned lower alkyl or, in a position higher thanthe 1-position halogen bonded to the above-mentioned lower alkoxy;hydroxy, hydroxy-lower alkyl or polyhydroxy-lower alkyl, or, assubstituent not directly bonded, again lower alkoxy, cycloalkyl-loweralkoxy, also phenyl-lower alkoxy, for example benzyloxy, loweralkylthio, alkyleneamino, or oxaalkyleneamino, for example pyrrolidino,piperidino or morpholino, pyrrol-1-yl, lower alkanoylamino or loweralkoxycarbonylamino, or ureido optionally substituted by lower alkyl,lower alkylsulphonylamino or N-lower alkyl lower alkylsulphonylamino;and in which n represents the number 0 or 1, alk represents an alkyleneradical having from 2 to 4 carbon atoms, the nitrogen atom and theoxygen atom or, if n is 0, the phenyl radical, being separated from oneanother by 2 or 3 carbon atoms, and R₁ and R₂ independently of oneanother each represents hydrogen or lower alkyl, but preferably hydrogenor methyl; and salts thereof, especially acid addition salts, moreespecially pharmaceutically acceptable non-toxic acid addition salts.

The invention relates especially to compounds of the formula I in whichAr represents phenyl which may be unsubstituted or substituted one tothree times, wherein as substituents there may be present, optionallysubstituted in the manner specified hereinafter, lower alkyl or loweralkoxy, also lower alkenyl, lower alkenyloxy, lower alkynyloxy, and/orcyano, and/or as substituents bonded directly or to the above-mentionedlower alkyl, lower alkoxy or lower alkenyl, one or more of loweralkanoyl, cycloalkyl, carbamoyl, lower alkylcarbamoyl or (hydroxy-loweralkyl)-carbamoyl, lower alkylsulphinyl and lower alkylsulphonyl; and/orfluorine or chlorine bonded directly or to the above-mentioned loweralkyl or, in a position higher than the 1-position, to theabove-mentioned lower alkoxy; hydroxy, hydroxy-lower alkyl or1,2-dihydroxy- or 2,3,-dihydroxy-lower alkyl, such as2,3-dihydroxypropyl, or, as substituent not directly bonded, again loweralkoxy, cycloalkyl-lower alkoxy such as cyclopropylmethoxy, alsophenyl-lower alkoxy, for example benzyloxy, lower alkylthio,pyrrol-1-yl, lower alkanoylamino, lower alkoxycarbonylamino, ureido,lower alkylsulphonylamino such as methylsulphonylamino, N-lower alkyllower alkylsulphonylamino such as N-methyl methylsulphonylamino; and inwhich n represents the integer 1, alk represents an alkylene radicalhaving from 2 to 4 carbon atoms, the nitrogen atom and the oxygen atombeing separated from one another by 2 carbon atoms, and R₁ and R₂represent hydrogen, and the phenyl radical carrying the amide and thehydroxy group is bonded preferably in its 4-position, and especially inits 5-position, to the remainder of the molecule; and salts thereof,especially acid addition salts, more especially pharmaceuticallyacceptable non-toxic acid addition salts.

The invention relates especially to compounds of the formula I in whichAr represents phenyl unsubstituted or substituted one or three times byhydroxy, n represents the integer 1, alk represents an alkylene radicalhaving from 2 to 4 carbon atoms, the nitrogen atom and the oxygen atombeing separated from one another by 2 carbon atoms, R₁ and R₂ representhydrogen or lower alkyl, such as methyl, and the phenyl radical carryingthe amide and the hydroxy group is bonded preferably in its 4-position,and especially in its 5-position to the remainder of the molecule, andsalts thereof, especially acid addition salts, more especiallypharmaceutically acceptable non-toxic acid addition salts.

The new compounds of the formula I are prepared in a manner known perse. They may be obtained, for example by reacting a compound of theformula ##STR3## with a compound of the formula ##STR4## in which

one of the groups Z₁ and Z₂ represents a reactive esterified hydroxygroup and the other represents the primary amino group, and

X₁ represents hydroxy,

or in which

X₁ and Z₁ together represent the epoxy group and

Z₂ represents the primary amino group, and Ar, n, alk, R₁ and R₂ havethe meanings given above, and, if desired, converting a compound whichmay be thus obtained into a different compound of the formula I and/orif desired, converting a resulting free compound into a salt or aresulting salt into a free compound and/or, if desired, separating aresulting isomeric mixture into its isomers or a resulting racemate intoits antipodes.

A reactive esterified hydroxy group Z₁ or Z₂ is a hydroxy groupesterified by a strong acid, especially a strong inorganic acid, such asa hydrohalic acid, especially hydrochloric, hydrobromic or hydriodicacid, or sulphuric acid, or by a strong organic acid, especially astrong organic sulphonic acid, such as an aliphatic or aromaticsulphonic acid, for example methanesulphonic acid,4-methylphenylsulphonic acid or 4-bromophenylsulphonic acid, and isespecially halogen, for example chlorine, bromine or iodine, oraliphatically or aromatically substituted sulphonyloxy, for examplemethylsulphonyloxy or 4-methylphenylsulphonyloxy.

The above reaction is carried out in a manner known per se, wherein,especially when using a starting material having a reactive esterifiedhydroxy group, the reaction is carried out advantageously in thepresence of a basic medium, such as an inorganic base, for example analkali metal or alkaline earth metal carbonate or hydroxide, or in thepresence of an organic basic medium, such as an alkali metal loweralkanolate, and/or an excess of the basic reactant, and usually in thepresence of a solvent or mixture of solvents, and, if necessary, whilstcooling or heating, for example in a temperature range of fromapproximately -20° C. to approximately 150° C., in an open or closedvessel and/or in an inert gas atmosphere, for example a nitrogenatmosphere.

Starting materials of the formula II are known or can be prepared in amanner known per se.

Starting materials of the formula III may be obtained, for example, byreacting a hydroxysalicylic amide with a dihaloalkane corresponding tothe meaning of alk, for instance a chloro-bromoalkane or dibromoalkane,in the presence of an alkaline condensing agent, such as an alkali metalcarbonate. These reactions are carried out in the customary manner,protecting groups at the hydroxy groups being simultaneously or, asdescribed hereinafter, subsequently split off.

The compounds of the formula I may also be prepared by a process whichis characterised in that in a compound of the formula ##STR5## in which

Ar₁ has the same meaning as Ar or represents a radical Ar that issubstituted by 1 or 2 groups that may be converted into hydroxy,

X₂, X₃ and X₄ each represents hydrogen or a substituent that may bereplaced by hydrogen, and

X₅ represents R₁, or

X₂ and X₃ and/or

X₄ and X₅ together represent a divalent radical that may be replaced bytwo hydrogen atoms, provided that at least one of the radicals X₂, X₃and X₄ is different from hydrogen, or at least Ar₁ represents a radicalAr that is substituted by 1 or 2 groups that may be converted intohydroxy, or at least X₂ and X₃ together or X₄ and X₅ together representa divalent radical that may be replaced by two hydrogen atoms,

or in a salt of the compound of the formula (IV) those of the groups X₂,X₃ and X₄, or X₂ and X₃ together, or X₄ and X₅ together, which are otherthan hydrogen are replaced by hydrogen atoms, and/or substituted hydroxypresent in a radical Ar₁ is converted into free hydroxy and, if desired,the additional process steps following the first process aresubsequently carried out.

The splitting off of the groups X₂, X₃ or X₄ X₂ and X₃ together or X₄and X₅ together, and of the hydroxy substituents present in a radicalAr₁ is effected by solvolysis for example by hydrolysis, alcoholysis, orby reduction including hydrogenolysis.

An especially suitable group X₃ or X₄ that is capable of being splitoff, or a hydroxy-protecting group in a radical Ar₁ is especially aα-aryl-lower alkyl group that is capable of being split off byhydrogenolysis, such as an optionally substituted 1-polyphenyl-loweralkyl group or 1-phenyl-lower alkyl group, in which substituents,especially of the phenyl moiety, may be, for example, lower alkyl, suchas methyl, or lower alkoxy, such as methoxy, and especially benzyl. Agroup X₃ and especially X₂ and X₄ and also hydroxy-protecting groups ina radical Ar₁ may also be radicals capable of being split off bysolvolysis, such as by hydrolysis or acidolysis, or radicals capable ofbeing split off by reduction, including hydrogenolysis, especially acorresponding acyl radical, such as the acyl radical of an organiccarboxylic acid, for example lower alkanoyl, such as acetyl, or aroyl,such as benzoyl, the acyl radical of a semi-ester of carbonic acid, suchas lower alkoxycarbonyl, for example methoxycarbonyl, ethoxycarbonyl, ortert.-butoxycarbonyl, 2-halo-lower alkoxycarbonyl, for example2,2,2-trichloroethoxycarbonyl or 2-iodoethoxycarbonyl, optionallysubstituted 1-phenyl-lower alkoxycarbonyl, for example benzyloxycarbonylor diphenylmethoxycarbonyl, or aroylmethoxycarbonyl, for examplephenacyloxycarbonyl, or an optionally substituted 1-polyphenyl-loweralkyl group, in which substituents, especially of the phenyl moiety, forexample have the meaning given above, and represent especially trityl.

A radical capable of being split off and formed by X₂ and X₃ and/or X₄and X₅ together, is especially a group that can be split off byhydrogenolysis, such as optionally substituted 1-phenyl-loweralkylidene, in which substituents, especially of the phenyl moiety, maybe, for example, lower alkyl or lower alkoxy, and especiallybenzylidene, and also groups that can be split off by solvolysis,especially by hydrolysis, such as lower alkylidene, for examplemethylene or isopropylidene, or 1-phenyl-lower alkylidene or which thephenyl moiety is optionally substituted by lower alkyl, such as methyl,or lower alkoxy, such as methoxy, especially benzylidene, orcycloalkylidene, for example cyclopentylidene or cyclohexylidene.

Starting materials that may be used in the form of salts are usedespecially in the form of acid addition salts, for example with mineralacids, and with organic acids.

Radicals X₂, X₃ and/or X₄ that can be split off by hydrogenolysis,especially optionally substituted 1-phenyl-lower alkyl groups, alsosuitable acyl groups, such as optionally substituted 1-phenyl-loweralkoxycarbonyl, and optionally substituted 1-phenyl-lower alkylidenegroups formed by the groups X₂ and X₃ and by X₄ and X₅ together, andalso hydroxy-protecting groups of this kind present in a radical Ar₁,can be split off by treating with catalytically activated hydrogen, forexample hydrogen in the presence of a nickel catalyst, such as Raneynickel, or a suitable noble metal catalyst.

Groups X₂, X₃ and/or X₄ that can be split off by hydrolysis, such asacyl radicals of organic carboxylic acids, for example lower alkanoyl,and of semi-esters of carbonic acid, for example lower alkoxycarbonyl,also for example trityl radicals, and also lower alkylidene,1-phenyl-lower alkylidene or cycloalkylidene groups formed by theradicals X₂ and X₃ and/or X₄ and X₅ together, and alsohydroxy-protecting groups of this kind present in a radical Ar₁, may,depending on the nature of such radicals, be split off by treating withwater under acidic or basic conditions, for example in the presence of amineral acid, such as hydrochloric acid or sulphuric acid, or an alkalimetal or alkaline earth metal hydroxide or carbonate, or an amine, suchas isopropylamine.

Radicals X₂, X₃ and/or X₄ and/or hydroxy-protecting groups in a radicalAr₁ that can be split off by acidolysis are especially certain acylradicals of semi-esters of carbonic acid, such as, for example,tert.-lower alkoxycarbonyl or optionally substituteddiphenylmethoxycarbonyl radicals, and the tert.-lower alkyl radical;such radicals can be split off by treating with suitable strong organiccarboxylic acids, such as lower alkanecarboxylic acids optionallysubstituted by halogen, especially fluorine, or especially withtrifluoroacetic acid (if necessary in the presence of an activatingagent, such as anisole), and with formic acid.

Radicals X₂, X₃ and/or X₄ and/or hydroxy-protecting groups in a radicalAr₁ that can be split off by reduction shall also include those groupswhich are split off when treated with a chemical reducing agent(especially with a reducing metal or a reducing metal compound). Suchradicals are, in particular, 2-halo-lower alkoxycarbonyl orarylmethoxycarbonyl, which can be split off, for example, by treatingwith a reducing heavy metal such as zinc, or with a reducing heavy metalsalt, such as a chromium(II) salt, for example chromium chloride oracetate, usually in the presence of an organic carboxylic acid, such asformic acid or acetic acid, and water.

Protecting groups positioned at the hydroxy groups optionally present ina radical Ar₁ correspond to the previously mentioned groups that can besplit off by means of the described methods and replaced by hydrogen,such groups being split off in the course of the described process atthe same time as other groups or subsequently in a separate processstep.

The above reactions are usually carried out in the presence of asolvent, or a mixture of solvents, wherein suitable reactants may alsoact simultaneously as such, and, if necessary, whilst cooling orheating, for example in an open or closed vessel, and/or in theatmosphere of an inert gas, for example nitrogen.

The starting material of the formula IV can be obtained analogously tothe above described process modifications, for example by treating acompound of the formula Ar₁ OH or a salt thereof with a compound of theformula ##STR6## in which

X₂ ^(o) represents the group X₂, wherein at least one of the groups X₃and X₂ ^(o) does not represent hydrogen, and

X^(o) represents a reactive esterified hydroxy group, or

X₂ ^(o) and X^(o) together represent a carbon-oxygen bond,

or in which

X₃ and X₂ ^(o) together represent a radical that is capable of beingsplit off and can be replaced by two hydrogen atoms bonded to the oxygenor nitrogen atom, and

X^(o) represents a reactive esterified hydroxy group,

or by treating a compound of the formula ##STR7## with a compound of theformula ##STR8## in which

X₂ ^(o) has the meaning given above for X₂, and

one of the groups Y₁ and Y₂ represents a reactive esterified hydroxygroup and the other represents the group of the formula --NH(X₃), inwhich X₃ has the meaning given above, provided that at least one of thegroups X₃ and X₂ does not represent hydrogen,

or in which

X₂ ^(o) and Y₁ form an oxygen-carbon bond and

Y₂ represents the group of the formula --NH(X₃) and X₃ does notrepresents hydrogen.

The above reactions are carried out in a manner known per se, forexample as described under the first process according to the invention.

Furthermore, the Schiff's base formed by reacting a compound of theformula ##STR9## with a carbonyl compound of the formula ##STR10## inwhich

R represents an alkyl radical corresponding to the alkylene radical alkand containing a carbonyl grouping that is separated from the oxygenatom or phenyl radical by at least one carbon atom, and

X₄ or

X₄ and X₅ together represent one of the mentioned protecting groups,

may be reduced, for example, with a borohydride, for instance sodiumborohydride, to the compound of the formula IV. The reduction can alsobe carried out by means of activated hydrogen in the presence of ahydrogenating catalyst, for example a platinum-on-carbon catalyst.

Carbonyl compounds of the formula (IVe) in which n is 1, may in turn beobtained in the customary manner by reacting a compound of the formula##STR11## with a compound of the formula R-Hal (IVg) in which R has themeaning given above, for example a haloketone, for examplechloroacetone.

The new compounds of the formula I may likewise be obtained by a processwhich is characterised in that, in a compound of the formula ##STR12##in which

X₆ is a reducible group of the formula --CH=N-alk-(Va) or --CH₂ -N=alk₁-(Vb) in which alk₁ represents an alkylylidene radical corresponding tothe radical alk, and

X₇ represents hydrogen or a radical that may be replaced by hydrogenunder the conditions for the reduction of X₆,

Ar₂ corresponds to a radical Ar, but optionally, instead of carrying oneor two hydroxy groups carries one or two OX₇ groups in which X₇ has themeaning given above, and

n is 0 or 1, wherein X₆ is always a reducible group Va or Vb,

the X₆ group is reduced, and simultaneously the X₇ group other thanhydrogen is replaced by hydrogen and, if desired, the additional processsteps following the first process are carried out.

A X₇ group that can be split off by hydrogenolysis is especially anα-aryl-lower alkyl group, such as an optionally substituted1-phenyl-lower alkyl group, in which the substituents may be, forexample, lower alkoxy, such as methoxy, and more especially benzyl.

Protecting groups that are positioned at the hydroxy groups optionallysubstituting the radical Ar₂ are the same as the groups mentionedpreviously for X₇ that can be split off by the described methods andreplaced by hydrogen, wherein such groups are split off during thecourse of the described process at the same time as other groups, orsplit off subsequently in a separate process step.

Starting substances of the formula V having a X₆ group of the formula Vbmay also exist in the isomeric form of ring tautomers of the formula##STR13## in which alk₂ has the same meaning as alk₁ and the oxygen andnitrogen atoms of the ring are bonded to the same carbon atom.

An alkylylidene group alk₁ is, for example ethylyidene, whilst analkylidene group alk₂ represents, for example methylene, ethylidene or1-methylethylidene.

The reduction of the nitrogen-carbon double bond in starting substancesof the formula V that contain a Va or Vb group as X₆, whilst Ar₂, X₇ andn have the meanings given under formula V, to form the nitrogen-carbonsingle bond can be carried out in a manner known per se, for example bytreating with catalytically activated hydrogen, such as hydrogen in thepresence of a suitable hydrogenating catalyst, for example a nickel,platinum or palladium catalyst, wherein X₇ groups capable of being splitoff by hydrogenolysis are simultaneously split off and replaced byhydrogen; alternatively, the reaction is carried out with a suitablehydride reducing agent, such as an alkali metal borohydride, e.g. sodiumborohydride. When using a hydride reducing agent, acyl radicals ofcarboxylic acids, such as, for example, acetic acid, bonded also tooxygen, may be present as X₇ radicals and may be split off in the sameoperation.

A starting material of the formula V may be prepared in a manner knownper se, optionally in situ, that is to say, under the conditions of theprocess described. Thus, a compound of the formula ##STR14## can bereacted with an amine of the formula ##STR15## to give a startingproduct of the formula V with the X₆ group of the formula Va.

By reacting a compound of the formula ##STR16## with a carbonyl compoundof the formula ##STR17## starting substances of the formula V can beobtained with a X₆ group of the formula (Vb). A modification of thesereactions consists in reacting a dibenzylamino compound corresponding toa compound of the formula (Vh) with the oxo compound of the formula (Vi)under the reducing conditions of the process. In this reaction thereducing agent used is especially catalytically activated hydrogen, forexample hydrogen in the presence of a heavy metal hydrogenating catalystor a mixture thereof, such as a palladium and/or platinum catalyst.Under these reaction conditions, X₇ groups which may be split off byhydrogenolysis, for example benzyl groups, are split off, and at thesame time the nitrogen-carbon double bond is reduced to thecorresponding nitrogen-carbon single bond.

Oxo compounds of the formula (Vi), in which n is 1, are in their turnobtained, for example, by reacting a dihydroxy compound of the formula##STR18## with a haloalkanone compound of the above-mentioned formulaR-Hal (IVf), for example chloroacetone, in the presence of an alkalinecondensing agent, for instance potassium carbonate, or of an organicbase, such as triethylamine.

The new compounds of the formula I may likewise be obtained by reactinga compound of the formula ##STR19## in which

Ar₃ has the same meaning as Ar, or represents a radical Ar that issubstituted by 1 or 2 groups that may be converted into hydroxy byaminolysis,

X₈ represents hydrogen or a group that can be split off by aminolysis,

or a reactive derivative of one of the carboxylic acids defined informula VI, with a compound of the formula

    HNR.sub.1 R.sub.2                                          (VII)

and at the same time splitting off optionally present X₈ radicals andreplacing them by hydrogen, and, if desired, carrying out the additionalprocess steps mentioned following the first process.

X₈ radicals that can be split off by aminolysis and especially byammonolysis are acyl radicals of organic carboxylic acids, e.g. aroyl,such as benzoyl, or lower alkanoyl, such as acetyl.

Reactive derivatives of the carboxylic acids defined in formula VI are,for example, the halides, such as the chlorides or bromides, the azides,and also acid anhydrides, especially mixed acid anhydrides with, forexample, lower alkanecarboxylic acids, such as acetic acid or propionicacid, or lower alkoxyalkanecarboxylic acids, such as 2-methoxyaceticacid. Reactive derivatives of carboxylic acids of the formula VI areespecially esters, for example with lower alkanols, such as methanol,ethanol, isopropanol or tert.-butanol, also with aryl lower alkanols,for instance benzyl alcohol optionally substituted by lower alkyl, forexample methyl, or lower alkoxy, for example methoxy, or with phenolswhich are optionally activated by suitable substituents, for example byhalogen, for instance 4-halo, such as 4-chloro; lower alkoxy, forinstance 4-lower alkoxy, such as 4-methoxy; 4-nitro; or 2,4-dinitro; forinstance 4-chlorophenol, 4-methoxyphenol, 4-nitrophenol or2,4-dinitrophenol; furthermore with cycloalkanols such as cyclopentanolor cyclohexanol, which may optionally be substituted by lower alkyl, forexample methyl. The reaction is carried out in a manner known per se,usually in the presence of an inert solvent, for example in atemperature range of from approximately -10° to 50° C. in a closedvessel.

The starting substances of the formula VI may be obtained in a mannerknown per se by reacting a compound of the formula (II), in which X₁ andZ₁ together represent the epoxy group, with an amino compound of theformula ##STR20## in which X₈ has the meaning given, or with a reactivederivative thereof.

The Schiff's base formed by reacting a compound of the formula ##STR21##with a carbonyl compound of the formula ##STR22## in which R representsthe alkyl radical corresponding to an alkylene radical alk andcontaining an oxo radical in place of the free valency thereof,

may also be reduced with a borohydride, for instance sodium borohydride.The reduction can also be carried out by means of activated hydrogen inthe presence of a hydrogenating catalyst, for example aplatinum-on-carbon catalyst.

Carbonyl compounds of the formula (VIc), in which n is 1, may in turn beobtained in a manner known per se by reacting a compound of the formula##STR23## with a compound of the formula

    R--Hal                                                     (IVg)

in which Hal represents halogen, especially chlorine.

The new compounds of the formula I may likewise be obtained by a processwhich is characterised in that, in a compound of the formula ##STR24##in which one or both hydroxy groups and/or hydroxy groups optionallypresent in the radical Ar are protected by those groups that can besplit off by hydrolysis and replaced by hydrogen, which are split offunder the conditions of the process and are replaced by hydrogen,

the --CN group is converted by hydrolysis into the --CONH₂ group and, atthe same time, optionally protected hydroxy groups are converted intofree hydroxy groups, and, if desired, the additional process stepsfollowing the first process are carried out.

The above reactions are carried out in a manner known per se. Thehydrolysis is effected in a basic, or, advantageously, in an acidicmedium, especially in the presence of concentrated aqueous mineralacids, such as, for example, concentrated hydrochloric acid, and, ifnecessary, whilst cooling or heating, for example in a temperature rangeof from approximately 0° to 60°, preferably from approximately 40°-50°,in an open or closed vessel and/or in an inert gas atmosphere, forexample in a nitrogen atmosphere.

The starting substances of the formula VIII may be obtained, forexample, by reacting a compound of the formula ##STR25## with a compoundof the formula ##STR26## in which Hal represents chlorine, bromine oriodine. The reaction is advantageously carried out in the presence of abasic medium in a manner known per se.

The compound VIIIb may in turn be obtained by the action of aceticanhydride on the oxime corresponding to the cyanide. This is expedientlycarried out by refluxing. The oxime may in its turn be prepared from thecorresponding aldehyde by refluxing with hydroxylamine hydrochloride inthe presence of alcoholic soda solution. The corresponding aldehyde mayin turn be prepared by reacting 2,4-dihydroxybenzaldehyde with aα,ω-dihalo-lower alkane, preferably in the presence of a basic medium.Alternatively, however, a hydroxysalicylonitrile, for example2,4-dihydroxybenzonitrile [Chem. Ber. 24, 3657 (1891)] or2,5-dihydroxybenzonitrile [(Helv. Chim. Acta 30, 149, 153 (1947)] may bereacted in an analogous manner with a non-geminal dihalo-lower alkane toform a compound of the formula VIIIb.

The new compounds of the formula I wherein Ar is substituted byhydroxy-lower alkyl or by polyhydroxy-lower alkyl, for example1,2-dihydroxy- or 2,3-dihydroxy-lower alkyl, such as 1,2-dihydroxy- or2,3-dihydroxypropyl, can be obtained by a process which is characterisedin that in a compound of the formula ##STR27## wherein Ar₄ represents aradical Ar which is substituted by a hydroxy-lower alkyl group of whichthe hydroxy group is substituted by a radical that can be split off andreplaced by hydrogen, or is substituted by a polyhydroxylower alkylgroup, for example by one of those mentioned, whereby at least onehydroxy group, or two hydroxy groups together, each of which is locatedat one of two adjacent hydrocarbon atoms, is (are) protected by aradical that can be split off and replaced by hydrogen, or in a saltthereof, these protecting groups, which can be identical or different,as well as optionally further protecting groups located at the nitrogenatom and/or at the oxygen atoms, are split off, and replaced byhydrogen, and, if desired, the additional process steps describedsubsequent to the first process are then carried out. Groups which canbe split off, and replaced by hydrogen, for example groups that can besplit off by means of solvolysis, such as hydrolysis, alcoholysis oracidolysis, or by means of reduction, including hydrogenolysis, forinstance as described above, are for example the radicals X₂ or X₄described above. Radicals X₂ or X₄ that can be split off by solvolysis,such as by hydrolysis or acidolysis, are for example acyl radicals, suchas acyl radicals of organic carboxylic acids, for example loweralkanoyl, such as acetyl, or aroyl, such as benzoyl, also for examplelower-alkoxy carbonyl, optionally substituted 1-phenyl-loweralkoxycarbonyl, for example benzyloxycarbonyl, also an optionallysubstituted 1-polyphenyl-lower alkyl group, for example trityl, andfurthermore the tetrahydropyranyl radical. Protecting groups locatedtogether at two adjacent hydroxy groups are for example: loweralkylidene, for example methylene or isopropylidene, or 1-phenyl-loweralkylidene, of which the phenyl moiety is optionally substituted bylower alkyl, such as by methyl or lower alkoxy, such as methoxy,particularly benzylidene, or cycloalkylidene, for examplecyclopentylidene or cyclohexylidene, also the carbonyl group.

Groups of the stated types which can be split off by hydrolysis, forexample acyl radicals of organic carboxylic acids, for examplelower-alkanoyl radicals, also for example lower-alkoxycarbonyl or tritylradicals, also tetrahydropyranyl radicals, also lower-alkylidene,1-phenyl-lower alkylidene or cycloalkylidene groups located together attwo hydroxy groups, as well as optionally further protecting groups ofthis kind located at the nitrogen atom and/or at the oxygen atoms, canbe split off, depending on the nature of such radicals, by treatmentwith water under acidic or basic conditions, for example in the presenceof a mineral acid, such as hydrochloric acid of sulfuric acid, or of anhydroxide or carbonate of an alkali metal or alkaline-earth metal. Acarbonyl group located at one of two adjacent hydroxy groups isadvantageously split off by means of basic agents, for instance analkali hydroxide, such as potassium hydroxide, or by means of an alkalimetal alcoholate, such as sodium ethylate or potassium tert.-butylate,whilst for example tetrahydropyranyl radicals are split off by means ofacid agents, for instance such as those mentioned. Radicals which can besplit off by acidolysis are for example those mentioned above for X₂and/or X₄, and are for example lower-alkoxycarbonyl or tert.-lower alkylradicals. Radicals of this kind can be split off, for example asdescribed above, by treatment with suitable strong organic carboxylicacids, such as by lower-alkane-carboxylic acids optionally substitutedby halogen, especially fluorine, particularly by treatment withtrifluoroacetic acid (if necessary in the presence of an activatingagent, such as anisole), as well as with formic acid. These reactionsare performed in a manner known per se.

A particularly suitable hydroxy protecting group that can be split offby hydrogenolysis is above all an α-aryl-lower alkyl group which can besplit off by hydrogenolysis, such as an optionally substituted1-polyphenyl-lower alkyl or 1-phenyl-lower alkyl group, whereinsubstituents, especially of the phenyl moiety, can be for example loweralkyl such as methyl, or lower alkoxy such as methoxy, and in particularbenzyl. A group which is located at two adjacent hydroxyl groupstogether and which can be split off by hydrogenolysis is for exampleoptionally substituted 1-phenyl-lower alkylidene, wherein substituents,especially of the phenyl moiety, can be for example lower alkyl such asmethyl, or lower alkoxy such as methoxy, and particularly benzylidene.Groups of the stated type which can be split off by hydrogenolysis canbe split off in the customary manner by treatment with catalyticallyactivated hydrogen, for example with hydrogen in the presence of anickel catalyst, such as Raney nickel, or of a suitable noble metalcatalyst.

Protective groups which are located at one or two hydroxyl groups andwhich can be split off by means of reduction are for example thosegroups which are split off on being treated with a chemical reducingagent, for instance as described above, for example2-halo-lower-alkoxycarbonyl or arylmethoxycarbonyl. Splitting off iseffected for instance by the methods described above, for example bymeans of zinc, or of a chromium(II) salt, or by means of an organiccarboxylic acid, such as formic acid.

Further protecting groups optionally present at the nitrogen atom and/orat the oxygen atoms correspond to the aforementioned groups that can besplit off and replaced by hydrogen by the methods mentioned, wherebysuch groups can be split off in the course of the described processsimultaneously with other groups or subsequently in a separate processstep.

Starting materials of the formula IX wherein Ar₄ is substituted by aradical which can be converted into a hydroxy-lower alkyl group orpolyhydroxy-lower alkyl group, such as 1,2- or 2,3-dihydroxy-lower alkylgroup, for example a 2,3-dihydroxypropyl group, can be obtained forexample by a process wherein a compound which optionally carriesprotecting groups on the nitrogen atom and/or on the oxygen atoms andwhich corresponds to the formula IX in which Ar₄ is a group of theformula

    --R.sub.9 --CH.sub.2 --Z.sub.3                             (IXa) or of the formula ##STR28## wherein R.sub.9 corresponds to a lower alkyl radical containing one carbon atom less, and R.sub.10 to a lower alkyl radical containing two carbon atoms less, and Z.sub.3 and Z.sub.4, which can be identical or different, are each a reactive esterified hydroxy group, for example halogen, such as chlorine and particularly bromine, is reacted with a salt of a carboxylic acid, for example with an alkali metal salt, for instance the potassium salt, of a lower alkanecarboxylic acid, for example acetic acid, or of an aromatic carboxylic acid, such as benzoic acid, to give the corresponding compound of the formula IX containing one or two acyloxy groups in the lower alkyl group located at the radical Ar.sub.4. Starting materials of the formula IX having a group IXa can be obtained by an addition reaction of for example hydrogen halide with an alkenyl radical bonded to the radical Ar, whereas starting materials having a group IXb are obtainable by an addition reaction of halogen, for example bromine, with an appropriate alkenyl radical.

Starting materials of the formula IX wherein Ar₄ is substituted forexample by a group of the formula ##STR29## in which X°₁₀ represents aradical which can be split off by hydrolysis, including alcoholysis oracidolysis, or by means of reduction, including hydrogenolysis, forexample one of such radicals mentioned above, and R₁₀ has the meaningalready defined, can be obtained by reacting for example a compound ofthe formula ##STR30## with epichlorohydrin, and reacting the resultingcompound of the formula ##STR31## for example with a5-(2-aminoethoxy)-salicylamide, which is optionally N-protected, such asN-benzylated, to obtain a compound of the formula IX wherein Ar₄contains the group IXc.

These reactions are performed in the customary manner, optionally withcooling or heating, and in a suitable solvent.

When selecting one of the above suitable processes for the preparationof compounds of the formula I, care must be taken that substituentspresent, especially of the Ar radicals, are not converted or split off,should such conversions or splitting off be undesirable. Thus,especially functionally modified carboxyl groups, such as esterified oramidated carboxyl groups, and also cyano groups, as substituents of Arradicals during solvolysis reactions, especially hydrolysis reactions,and also during reducing operations, may participate in the reaction andbe converted. On the other hand, simultaneous conversion of substituentsmay be desirable; for example, unsaturated substituents, such as loweralkenyl, may be reduced, for example to lower alkyl, under theconditions of a reducing process used according to the invention.

Within the scope of the definition of the compounds of the formula I,compounds obtained in the usual manner according to the invention can beconverted into other final products, for example by modifyingintroducing or splitting off suitable substituents in resultingcompounds.

For instance, unsaturated substituents, for example lower alkenyl, inresulting compounds may be reduced, for example by treating withcatalytically activated hydrogen.

Furthermore, in resulting compounds having halogen-substituted radicalsof an aromatic nature, the halogen may be replaced by hydrogen, forexample by treating with hydrogen in the presence of a customaryhydrogenating catalyst, such as Raney nickel, or palladium on carbon.

Free carboxyl groups in the Ar radicals, may be esterified in thecustomary manner, for example by reacting with an appropriate alcohol,advantageously in the presence of an acid, such as a mineral acid, forexample sulphuric acid or hydrochloric acid, or in the presence of adehydrating agent, such as dicyclohexylcarbodiimide, or by reacting witha corresponding diazo compound, for example diazomethane. Theesterification may also be carried out by reacting a salt, preferably analkali metal salt of the acid, with a reactive esterified alcohol, forexample an appropriate halide, such as chloride.

Free carboxyl groups may be amidated in the usual manner, for example byreaction with ammonia, or with a primary or secondary amine,advantageously in the presence of a dehydrating agent, such asdicyclohexyl carbodiimide or by converting the carboxyl group into ahalocarbonyl group, for example a chlorocarbonyl group, and thenreacting with ammonia or with a primary or secondary amine.

In compounds that contain an esterified carboxyl group, the latter maybe converted into a free carboxyl group in the customary manner, forexample by hydrolysis, preferably in the presence of strong bases, suchas an alkali metal hydroxide, for example sodium or potassium hydroxide,or in the presence of strong acids, for example a strong mineral acid,such as a hydrohalic acid, for example hydrochloric acid, or sulphuricacid.

In compounds having an esterified carboxyl group as substituent, thelatter may be converted into the corresponding carbamoyl group in thecustomary manner, for example by ammonolysis or aminolysis with ammoniaor a primary or secondary amine.

Compounds having a carbamoyl group and preferably R₁ and R₂ radicalsthat do not represent hydrogen may be dehydrated to the correspondingcyano compounds in the customary manner, for example by the action ofdehydrating agents, such as phosphorus pentoxide or phosphorusoxychloride, preferably at relatively high temperatures.

Compounds that contain a cyano substituent may be hydrolysed in thecustomary manner, for example in the presence of concentrated aqueousmineral acids, or alkali metal hydroxides, to the correspondingcarbamoyl compounds, or directly to the carboxyl compounds.

Compounds having a cyano group as substituent may be alcoholysed to thecorresponding compounds having esterified carboxyl groups in thecustomary manner, for example by the addition of alcohols in thepresence of an anhydrous acid, such as hydrogen chloride, and bysubsequent hydrolysis of the resulting imido ester.

As in the preparation processes, care must also be taken when carryingout the additional steps that undesirable side reactions that may resultin the conversion of additional groupings, do not occur.

The above-described reactions may optionally be carried out at the sametime or in succession, or in any sequence. If necessary, they arecarried out in the presence of diluents, condensing agents and/orcatalytically active agents, at reduced or elevated temperature, in aclosed vessel under pressure and/or in an inert gas atmosphere.

Depending on the process conditions and starting substances, the newcompounds are obtained in free form or in the form of their salts, alsocovered by the invention, wherein the new compounds or salts thereof mayalso be in the form of hemi-, mono-, sesqui- or polyhydrates. Acidaddition salts of the new compounds may be converted into the freecompounds in a manner known per se, for example by treating with basicagents, such as alkali metal hydroxides, carbonates or bicarbonates, orwith ion-exchangers. On the other hand, resulting free bases withorganic or inorganic acids, for example with the acids mentioned, mayform acid addition salts, wherein the acids used for their preparationare especially those that are suitable for the formation ofpharmaceutically acceptable salts.

These or different salts, especially acid addition salts of the newcompounds, such as, for example, oxalates or perchlorates, may also beused for the purification of the resulting free bases, by converting thefree bases into salts, separating them off and purifying them andliberating the bases from the free salts.

Depending on the choice of starting substances and working methods, thenew compounds may be obtained as optical antipodes or racemates, or,provided they contain at least two asymmetric carbon atoms, as mixturesof racemates. The starting substances can also be used as specificoptical antipodes.

Resulting mixtures of racemates may be separated into the twostereoisomeric (diastereoisomeric) racemates on the basis ofphysical-chemical differences in the diastereoisomers in known manner,for example by chromatography and/or fractional crystallisation.

Resulting racemates may be decomposed into the antipodes by methodsknown per se, for example by recrystallisation from an optically activesolvent, by treating with suitable microorganisms, or by reacting withan optically active substance forming salts with the racemic compound,especially acids, and separating the salt mixture obtained in thismanner, for example on the basis of different solubilities, into thediasteroisomeric salts, from which the free antipodes may be liberatedby the action of suitable agents. Especially useful, optically activeacids are, for example, the D- and L-forms of tartaric acid,di-O,O'-(p-toluoyl)tartaric acid, malic acid, mandelic acid,camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid.Advantageously, the more active of the two antipodes is isolated.

The invention relates also to those forms of the process according towhich a compound that may be obtained as intermediate at any stage ofthe process is used as starting material, and the remaining processsteps are carried out or the process is interrupted at any stage, or inwhich a starting substance is formed under the reaction conditions or inwhich a reactant is optionally present in the form of its salts.

Advantageously, the starting materials used for carrying out thereactions according to the invention are those which yield the groups offinal substances mentioned initially, and especially those which lead tothe specifically described or emphasized final substances.

The starting materials are known, or if they are new, can be preparedaccording to methods known per se, as described above, for exampleanalogously to the Examples. The invention relates also to the newstarting materials and to intermediates that may be obtained accordingto the process.

The new compounds may, for example, be used in the form ofpharmaceutical preparations which contain a pharmacologically activeamount of active substance, optionally together with pharmaceuticallyacceptable carriers that are suitable for enteral, for example oral, orparenteral, administration, and that may be organic or inorganic, solidor liquid. Thus, tablets or gelatin capsules are used which contain theactive substance together with diluents, for example lactose, dextrose,sucrose, mannitol, sorbitol or cellulose and/or glycerin and/orlubricants, for example silica, talc, stearic acid or salts thereof,such as magnesium or calcium stearate, and/or polyethylene glycol.Tablets may likewise contain binders, for example magnesium aluminiumsilicate, starches, such as maize, corn, rice or arrowroot starches,gelatin, tragacanth, methylcellulose, sodium carboxymethylcelluloseand/or polyvinylpyrrolidone, and, if desired, disintegrating agents, forexample starches, agar, alginic acid, or a salt thereof, such as sodiumalginate, and/or effervescing mixtures, or adsorption agents, colorants,flavouring substances and sweeteners. Furthermore, the newpharmacologically active compounds may be used in the form ofparenterally administerable preparations or infusion solutions. Suchsolutions are preferably isotonic, aqueous solutions or suspensions,wherein these, for example in the case of lyophilised preparations thatcontain the active substance alone or together with a carrier, forexample mannitol, can be prepared before use. The pharmaceuticalpreparations may be sterilised and/or contain auxiliaries, for examplepreservatives, stabilisers, wetting and/or emulsifying agents,solubilisers, salts for regulating the osmotic pressure and/or buffers.The present pharmaceutical preparations which, if desired, may containother pharmacologically active substances, are prepared in a mannerknown per se, for example by means of conventional mixing, granulating,coating, dissolving, or lyophilising processes, and contain fromapproximately 0.1% to 100%, especially from approximately 1% toapproximately 50%, and in the case of lyophilisates up to 100%, of theactive substances.

The dosage may be dependent on various factors, such as the method ofadministration, species, age and individual condition. Thus, the dosesto be administered orally to warm-blooded animals daily in one or more,preferably at most 4 individual doses, lie between 0.03 and 3 mg/kg forβ-receptor blockers of the formula I, and, for warm-blooded animals ofapproximately 70 kg body weight, preferably between approximately 0.004and approximately 0.08 g, and for β-receptor stimulators of the formulaI, between 0.01 and 1 mg/kg and between approximately 0.002 and 0.04 g,respectively.

The following Examples serve to illustrate the invention; temperaturesare given in degrees Centigrade.

EXAMPLE 1

21 g of crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]-propan-2-ol,dissolved in 170 ml of methanol, are hydrogenated with the addition of 2g of Pd/C-catalyst (5%) under normal conditions until hydrogenabsorption ceases. By filtration and concentration of the solution byevaporation, an oil is obtained which crystallises when triturated withtoluene. After recrystallisation of the crystalline residue from ethylacetate, the resulting1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olmelts at 117°-125°, (mixture of the diastereoisomers).

The starting material is prepared as follows:

(1a) In accordance with the method described by Irvine et al., Synthesis1972, 568, using an excess of acetone, 2,5-dihydroxybenzamide isconverted into2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-one having amelting point of 215°-216°.

(1b) 70 g of 2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazine-4-oneare refluxed for 30 hours, whilst stirring, in 400 ml of acetonitrilewith 100 g of potassium carbonate and 32 ml of chloroacetone. After theaddition of a further 3.2 ml of chloroacetone, the reaction mixture isheated for a further 15 to 20 hours. The still warm reaction mixture isfiltered, the residue thoroughly washed with acetone and the combinedfiltrate is concentrated by evaporation. The crystalline residue isrecrystallised from toluene and yields2,3-dihydro-2,2-dimethyl-6-(2-oxopropoxy)-4H-1,3-benzoxazin-4-one havinga melting point of 125°-126°.

(1c) 74 g of crude2,3-dihydro-2,2-dimethyl-6-(2-oxopropoxy)-4H-1,3-benzoxazin-4-oneobtained according to Example 1b) are heated in a mixture of 150 ml ofdioxan and 450 ml of 2N hydrochloric acid for 45 minutes on a waterbath. The solvent is evaporated off and the crystalline residuetriturated with water and then suction-filtered. By recrystallisationfrom isopropanol, 5-(2-oxopropoxy)salicylamide having a melting point of152°-154° is obtained.

(1d) 55 g of benzylamine and 1.25 g of concentrated sulphuric acid areadded to a solution of 104.5 g of 5-(2-oxopropoxy)salicylamide in 1000ml of methanol and hydrogenated in the presence of 3.0 g ofPt/C-catalyst at room temperature and atmospheric pressure until 1equivalent of hydrogen has been absorbed. The catalyst is filtered off,approximately 10 g of powdered calcium carbonate are stirred into thesolution and the solution is filtered again and concentrated byevaporation. The oil remaining crystallises from isopropanol. Repeatedrecrystallisation from isopropanol yields5-[2-(benzylamino)propoxy]salicylamide having a melting point of102°-104°.

(1e) A solution of 10.2 g of1-(2,3-epoxypropoxy)-4-(2-methoxyethoxy)benzene and 11.0 g of5-[2-(benzylamino)-propoxy]salicylamide in 200 ml of isopropanol isrefluxed for 24 hours. By concentration of the solution by evaporation,crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]-propan-2-olis obtained as an oil which is used in its crude state fordebenzylation.

EXAMPLE 2

6.1 g of crude1-[N-[2-(4-carbamoyl-3-hydroxyphenoxy)-1-methylethyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]-propan-2-olare hydrogenated and worked up analogously to Example 1. Afterrecrystallisation from isopropanol,1-[2-(4-carbamoyl-3-hydroxyphenoxy)-1-methylethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olis obtained as a diastereoisomeric mixture having a melting point of120°-121°.

The starting material is prepared as follows:

(2a) Analogously to Example (1a), from 2,4-dihydroxybenzamide there isobtained 2,3-dihydro-2,2-dimethyl-7-hydroxy-4H-1,3-benzoxazin-4-onehaving a melting point of 249°-251°.

(2b) Analogously to Example (1b), from 168 g of2,3-dihydro-2,2-dimethyl-7-hydroxy-4H-1,3-benzoxazin-4-one, 305 g ofpotassium carbonate and 88 ml of chloroacetone in 1.2 liters ofacetonitrile, there is obtained by boiling for 28 hours and subsequentworking up,2,3-dihydro-2,2-dimethyl-7-(2-oxopropoxy)-4H-1,3-benzoxazin-4-one havinga melting point of 160°-162° (from isopropanol).

(2c) 75 g of crude2,3-dihydro-2,2-dimethyl-7-(2-oxopropoxy)-4H-1,3-benzoxazin-4-one and 32g of benzylamine, dissolved in 1000 ml of methanol, are hydrogenatedunder normal conditions with the addition of 0.75 g of concentratedsulphuric acid and 1.6 g of Pt/C-catalyst (5%) until hydrogen absorptionceases. After filtering off the catalyst and evaporating off thesolvent, the oily residue is divided between 300 ml of ethyl acetate and500 ml of 2N hydrochloric acid. Crude2,3-dihydro-2,2-dimethyl-7-[(2-benzylamino)propoxy]-4H-1,3-benzoxazin-4-oneis isolated as an oil from the aqueous phase by rendering alkaline withconcentrated ammonia (whilst cooling with ice) and extracting with ethylacetate, and this oil can be put to further use in its crude state.

(2d) A mixture of 100 g of crude2,3-dihydro-2,2-dimethyl-7-[(2-benzylamino)propoxy]-4H-1,3-benzoxazin-4-one,100 ml of isopropanol and 100 ml of isopropylamine is refluxed for 1hour and then concentrated by evaporation. The oil remainingcrystallises when triturated with ether. The crystals aresuction-filtered and washed with a little isopropanol. In this manner,4-[2-benzylamino)propoxy]-salicylamide having a melting point of121°-123° is obtained.

(2e) Analogously to Example (1e), using4-[2-(benzylamino)propoxy]salicylamide instead of the 5-derivative,1-[N-[2-(4-carbamoyl-3-hydroxyphenoxy)-1-methylethyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olis obtained as an oil which is used in its crude state fordebenzylation.

EXAMPLE 3

Analogously to Example 2, by debenzylation of 22 g of crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)ethyl]-benzylamino]-3-[2-[N-(2-hydroxyethyl)carbamoylmethoxy]-phenoxy]propan-2-olthere is obtained1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-[N-(2-hydroxyethyl)-carbamoylmethoxy]phenoxy]propan-2-olhaving a melting point of 157°-159°. A hydrochloride is formed having amelting point of 126°-127° (from isopropanol/water 1:1).

The starting material is obtained in the following manner:

(3a) A mixture of 48.2 g of2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-one, 70 g ofpotassium carbonate and 250 ml of 1,2-dibromoethane is refluxed for 4hours whilst stirring. The semi-liquid reaction mixture is extracted 3to 4 times whilst hot with 1 liter of methanol each time; the combinedmethanol extracts are concentrated by evaporation and the residue isrecrystallised from methanol.6-(2-Bromoethoxy)-2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazin-4-onehaving a melting point of 190°-195° is obtained.

(3b) A mixture of 60 g of6-(2-bromoethoxy)-2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazine-4-one and110 ml of benzylamine is stirred for 30 minutes in a bath at 80°. Thereaction mixture is then brought to pH 3-4 with concentratedhydrochloric acid, whilst cooling with ice, and left to crystallise.After 2-4 hours, the crystals are suction-filtered, washed with 50 ml ofwater and 50 ml of ethyl acetate and dried. The resulting5-[(2-benzylamino)ethoxy]salicylamide hydrochloride melts at 214°-216°.The base liberated therefrom melts at 107°-108° (from ethylacetate/ether).

(3c) 12 g of [2-(2,3-epoxypropoxy)phenoxy]-N-(2-hydroxyethyl)acetamideand 11.5 g of 5-[(2-benzylamino)-ethoxy]salicylamide are refluxed in 70ml of isopropanol for 18-24 hours. The oily residue of evaporation isused for debenzylation in its crude state.

EXAMPLE 4

21 g of crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olare hydrogenated analogously to Example 1. After hydrogen absorption hasceased, the product is dissolved in hot methanol and the catalyst isfiltered off. By concentration of the methanolic solution byevaporation,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olis obtained as crystals having a melting point of 157°-158°. A neutralfumarate is formed having a melting point of 150°-151° (frommethanol/acetone).

The starting material may be prepared as follows:

(4a) A solution of 9 g of1-(2,3-epoxypropoxy)-4-(2-methoxyethoxy)benzene and 8.6 g of5-[(2-benzylamino)ethoxy]-salicylamide in 60 ml of isopropanol isrefluxed for 24 hours. The crude product obtained by concentration byevaporation is divided between 50 ml of 2N hydrochloric acid and 100 mlof ether. The aqueous phase is separated off, and rendered alkaline withconcentrated ammonia solution whilst cooling with ice. By extractionwith approximately 300 ml of ethyl acetate, drying (MgSO₄), andconcentration by evaporation, the crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)ethyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]-propan-2-olis isolated as an oil and used without further purification fordebenzylation.

EXAMPLE 5

The following are prepared in a manner analogous to Examples 4 and 4a):

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-phenoxypropan-2-ol,melting point 154°-156°, (from methanol,

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-[2-(methoxycarbonylamino)ethoxy]phenoxy]propan-2-ol,melting point 150°-151°, (from methanol),

1-(4-acetamidophenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-ol,melting point 185° (from methanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-methylphenoxy)propan-2-ol,melting point 129°-130°, (from isopropanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methylphenoxy)propan-2-ol,melting point 154°-155° (from methanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)-5-ethylamino]-3-(2-methylindol-4-yloxy)propan-2-ol,melting point 180°-194° (from ethyl acetate),

5-[3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-cis-naphthalenediolas diastereoisomeric mixture, melting point 108°-118° (from methanol),

4-[2-hydroxy-3-[(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]propoxy]phenylacetamide,melting point 149°-151° (from methanol); a different crystalmodification has a melting point of 181°-182° (fromdimethylformamide/water),

4-[2-hydroxy-3-[(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]propoxy]phenoxyacetamidemelting point 168°-170° (from DMF/water),

N-[4-[2-hydroxy-3-[(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]propoxy]phenyl]-N',N'-dimethylurea, melting point 140°-142° (with decomposition) (from methanol),

1-(4-butyroylamino-2-acetylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-ol,

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-methoxyphenoxy)propan-2-ol,melting point 125°-126°, (from methanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2,3-dimethylphenoxy)propan-2-ol,melting point 129°-131° (from methanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(2-methoxyethoxy)phenoxy]propan-2-ol,melting point of the hydrochloride 157°-160° (from methanol-acetone),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[3-(2-methoxyethoxy)phenoxy]propan-2-ol,

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(pyrrol-1-yl)phenoxy]propan-2-ol,melting point 138°-140° (sinters at temperatures of 135° and above),

1-(2-carbamoylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]propan-2-ol,melting point of hydrochloride 149°-152° (from methanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-trifluoromethylphenoxy)propan-2-ol,melting point 195°-196° (from methanol),

1-(2-acetylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-ol,melting point 122°-124° (from isopropanol),

1-[4-[2-(acetamido)ethoxy]phenoxy]-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-olas a hydrochloride, melting point 191°-192° (from methanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methylpyridin-2-yloxy)propan-2-ol,melting point 147°-148° (from methanol,

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methyl-4-methylsulphonylphenoxy)propan-2-ol,melting point 128°-131° (from acetonitrile),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(1-naphthyloxy)propan-2-ol,melting point 131°-134° (from isopropanol).

EXAMPLE 6

Analogously to Examples 2 and (2e), from 10.5 g of4-[(2-benzylamino)propoxy]salicylamide and 8.5 g of3,4-dihydro-5-(2,3-epoxypropoxy)-2-(1H)-quinolinone and by debenzylatingthe reaction product, there is obtained5-[3-[2-(4-carbamoyl-3-hydroxyphenoxy)-1-methylethylamino]-2-hydroxypropoxy]-3,4-dihydro-2-(1H)-quinolinoneas a diastereoisomeric mixture which forms a hydrochloride having amelting point of 239°-245° (from methanol).

EXAMPLE 7

A solution of 16 g of crude1-[N-[3-(3-carbamoyl-4-hydroxyphenyl)propyl]benzylamino]-3-[4-(2-methoxyethoxy)-phenoxy]propan-2-olis hydrogenated analogously to Example 1. The hydrogenating solution isneutralised with a solution of hydrochloric acid gas in methanol,concentrated by evaporation and crystallised from acetone. In thismanner1-[3-(3-carbamoyl-4-hydroxyphenyl)propylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olis obtained as a hydrochloride having a melting point of 194°-200°.

The starting material may be prepared as follows:

(7a) 3-(4-hydroxyphenyl)propionic acid is converted into the mixedanhydride and then, with benzylamine, into the3-(4-hydroxyphenyl)propionic acid N-benzylamide (m.p. 115°-116°).

(7b) Flask-synthesis (CO₂, 180°, 4 hours, 55 bar) with the sodium saltof the compound prepared according to (7a) yields3-(3-carboxy-4-hydroxyphenyl)propionic acid N-benzylamide having amelting point of 180°-181°.

(7c) Esterification with methanol/sulphuric acid while refluxing for 48hours yields 3-(3-methoxycarbonyl-4-hydroxyphenyl)propionic acidN-benzylamide having a melting point of 139°-140° (from ethyl acetate).

(7d) Reacting with benzyl bromide/potassium carbonate in acetone(refluxing for 15 hours) yields3-(4-benzyloxy-3-methoxycarbonylphenyl)propionic acid N-benzylamide as ayellowish oil.

(7e) Selective reduction of the amide group with diborane intetrahydrofuran (for 48 hours, 20°-25°) with gentle catalyticdebenzylation of the product (Pd/C-catalyst 5%, 15°-20° in methanol)yield N-[3-(4-hydroxy-3-methoxy-carbonylphenyl)propyl]benzylamine havinga melting point of 75°-77° (from isopropanol).

(7f) 200 ml of concentrated ammonia are added to a solution of 27 g ofN-[2-(4-hydroxy-3-methoxycarbonylphenyl)propyl]benzylamine in 100 ml ofdioxan and the solution is left to stand for 3-4 days at 20°-30°. Thereaction mixture is concentrated by evaporation, divided between waterand ethyl acetate and the organic phase is separated. Usual working upyields crude N-[3-(3-carbamoyl-4-hydroxyphenyl)propyl]benzylamine as anoil which is processed further without further purification.

(7g) A solution of 6.7 g of1-(2,3-epoxypropoxy)-4-(2-methoxyethoxy)benzene and 8.5 g ofN-[3-(3-carbamoyl-4-hydroxyphenyl)propyl]benzylamine in 70 ml ofisopropanol is refluxed for 18 hours and then concentrated byevaporation. The resulting crude1-[N-[3-(3-carbamoyl-4-hydroxyphenyl)propyl]benzylamino]-3-[4-(2-methoxyethoxy)-phenoxy]propan-2-olis used in its crude state for debenzylation.

EXAMPLE 8

A solution of 5 g of crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethyl]benzylamino]-3-(4-benzyloxyphenoxy)propan-2-ol(with diastereoisomer pair A present in greater amount) in 50 ml ofmethanol is hydrogenated under normal conditions in the presence of 0.5g of Pd/C-catalyst (5%) until 2 equivalents of hydrogen have beenabsorbed, whereupon the hydrogenation ceases. The reaction mixture isfiltered, 0.52 g of fumaric acid is dissolved in the filtrate and thesolution is concentrated to approximately 10 ml. After standing for arelatively long period of time, crystals of the neutral fumarate of1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-(4-hydroxyphenoxy)propan-2-olform, having a melting point of 195°-198° (pure enantiomer pair A).

In an analogous manner, by debenzylation of the enantiomer pair Bpresent in greater amount the fumarate of the pure enantiomer pair Bhaving a melting point of 181°-185° can be prepared.

The starting materials can be prepared as follows:

(8a) A solution of 49.8 g of2,3-dihydro-2,2-dimethyl-6-(2-oxopropoxy)-4H-1,3-benzoxazin-4-one and21.4 g of benzylamine in 700 ml of methanol is hydrogenated with theaddition of 0.5 g of concentrated sulphuric acid and 3 g ofPt/C-catalyst (5%) until the equivalent amount of hydrogen has beenasborbed. Working up analogously to Example (1d) yields6-(2-benzylaminopropoxy)-2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazin-4-onehaving a melting point of 127°-129° (from isopropanol).

(8b) A solution of 15.4 g of benzyl [4-(2,3-epoxypropoxy)-phenyl]etherand 17.0 g of6-(2-benzylaminopropoxy)-2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazin-4-onein 100 ml of isopropanol is refluxed for 24 hours, filtered andconcentrated by evaporation. Trituration of the residue withapproximately 200 ml of ether results in crystallisation of1-[N-[2-(2,3-dihydro-2,2-dimethyl-4-oxo-4H-1,3-benzoxazin-6-yloxy)-1-methylethyl]benzylamino]-3-(4-benzyloxyphenoxy)propan-2-olhaving a melting point of 149°-160° (in which the enantiomer pair A ispresent in greater amount).

By concentrating the ether solution by evaporation and recrystallisingfrom a little isopropanol, after standing for several days crystalshaving a melting point of 59°-62° (rest up to 140°) are obtained. Themother liquor which no longer crystallises is separated off. It containsthe enantiomer pair B in greater amount.

(8c) 5.2 g of the crystals having a melting point of 149°-160° mentionedunder (8b) are refluxed in a mixture of 20 ml of isopropylamine and 40ml of isopropanol for 1 hour and then concentrated by evaporation. Theresulting crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethyl]-benzylamino]-3-(4-benzyloxyphenoxy)propan-2-ol(5g) obtained as an oil contains the enantiomer pair A in greater amountand is used without further purification for debenzylation.

The procedure with the oil from Example (8b) containing the enantiomerpair B in greater amount is analogous.

EXAMPLE 9

80 ml of isopropylamine are added to a solution of 18.0 g of crude1-[2-(2,3-dihydro-2,2-dimethyl-4-oxo-4H-1,3-benzoxazin-6-yloxy)-1-methylethylamino]-3-(4-methylcarbamoylphenoxy)propan-2-olin 300 ml of methanol and the solution is refluxed for 1 hour. Thereaction mixture is concentrated by evaporation and the oil remaining iscrystallised from 80 ml of isopropanol.1-[2-(3-Carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-(4-methylcarbamoylphenoxy)propan-2-olhaving a melting point of 172°-175° (diastereoisomeric mixture) isobtained.

The starting materials can be obtained as follows:

(9a) A solution of 13.6 g of6-(2-benzylaminopropoxy)-2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazin-4-oneand 10.4 g of 4-(2,3-epoxypropoxy)-N-methylbenzamide in 80 ml ofisopropanol is refluxed for 30 hours. The residue remaining after thesolvent has been evaporated off is divided between ether and 2Nhydrochloric acid. The acidic, aqueous phase is separated off, and,whilst cooling with ice, rendered alkaline with approximately 10%aqueous ammonia solution and extracted with ethyl acetate. By separatingoff, drying (MgSO₄) and concentrating the ethyl acetate extract byevaporation, the crude1-[N-[2-(2,3-dihydro-2,2-dimethyl-4-oxo-4H-1,3-benzoxazin-6-yloxy)-1-methylethyl]benzylamino]-3-(4-methylcarbamoylphenoxy)propan-2-olis obtained as an oil which may be used without further purification forcatalytic debenzylation.

(9b) The product obtained according to (9a) is dissolved in 300 ml ofmethanol and, with the addition of 2.8 g of Pd/C-catalyst (5%) and afurther addition of 1.4 g of catalyst, is hydrogenated until hydrogenabsorption ceases. The methanolic solution of1-[2-(2,3-dihydro-2,2-dimethyl-4-oxo-4H-1,3-benzoxazin-6-yloxy)-1-methylethylamino]-3-(4-methylcarbamoylphenoxy)propan-2-olobtained after the catalyst has been filtered off is further processeddirectly.

EXAMPLE 10

Exactly in accordance with the method described in Example 9, using4-(2,3-epoxypropoxy)-(2-methoxyethyl)-benzene,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-[4-(2-methoxyethyl)phenoxy]propan-2-olis obtained as a diastereoisomeric mixture having a melting point of139°-142° (from ethyl acetate).

EXAMPLE 11

A mixture of 9.0 g of6-(2-bromoethoxy)-2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazin-4-one and14.5 g of 1-(2-allyloxyphenoxy)-3-aminopropan-2-ol is stirred for 1 hourin a bath at 110°-120°. The melt is then extracted by boiling with 100ml of isopropanol, the solution is filtered and concentrated byevaporation. The residue is divided between 400 ml of ethyl acetate and50 ml of 2N potassium bicarbonate solution. By concentration byevaporation and fractional crystallisation,1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-propan-2-olhaving a melting point of 147°-148° (from isopropanol) is obtained fromthe ethyl acetate solution. The neutral fumarate of the compound meltsat 136°-137° (from methanol).

EXAMPLE 12

A mixture of 11.2 g of 1-(2-allyloxyphenoxy)-3-aminopropan-2-ol and 10.5g of 5-(2-oxopropoxy)salicylamide is boiled using a water separator in200 ml of toluene with the addition of a few drops of acetic acid. Afterthe splitting off of water has ceased (after about 2-3 hours), thesolution is concentrated by evaporation, the dark red residue isdissolved in 300 ml of ethanol and a total of 5.7 g of sodiumborohydride is added in portions whilst stirring. The temperatureincreases during this operation to 36°. The reaction mixture is stirredfor a further 2 hours at 20°-30°, and left to stand overnight. Whilstcooling with ice, it is then brought to pH 3-4 with approximately 6Nhydrochloric acid, filtered and concentrated by evaporation. The residueis divided between 100 ml of water and 100 ml of ethyl acetate, theaqueous phase is separated off, rendered alkaline with concentratedammonia and extracted with 200 ml of ethyl acetate. Working up of theorganic phase yields crude oily1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]propan-2-olas an enantiomer mixture. By slow crystallisation from isopropanol thetwo pure enantiomer pairs having melting points of 123°-125° and98°-102° respectively are obtained.

EXAMPLE 13

A mixture of 6.5 g of 5-(2-bromoethoxy)salicylamide and 8.9 g of1-(2-allyloxyphenoxy)-3-aminopropan-2-ol is melted in an oil bath at100° and stirred for 1 hour using a magnetic stirrer. The working up iscarried out analogously to Example 11 and yields1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-propan-2-olhaving a melting point of 147°-148° (from isopropanol).

The salicylamide compound used as starting material may be obtained asfollows:

(13a) 30.0 g of6-(2-bromoethoxy)-2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazin-4-one arerefluxed in a mixture of 100 ml of dioxan and 100 ml of 6N hydrochloricacid, whilst stirring, for 1.5 hours. The crystals obtained afterconcentrating the reaction mixture by evaporation are washed with 50 mlof water and dried in vacuo. The resulting 5-(2-bromoethoxy)salicylamidemelts at 141°-143°.

EXAMPLE 14

By using the corresponding 1-aryloxy-3-aminopropan-2-ols the followingcompounds are obtained in a manner analogous to Example 13:

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-cyanophenoxy)propan-2-ol,melting point 121°-124° (from ethanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,melting point 157°-158° (from isopropanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(prop-2-ynyloxy)phenoxy]propan-2-ol,melting point 140°-141° (from ethanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methylthioethoxy)phenoxy]propan-2-ol,which forms a hydrochloride having a melting point of 202°-204° (frommethanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-allylphenoxy]propan-2-ol,which forms a neutral fumarate having a melting point of 165°-166° (fromethanol).

EXAMPLE 15

Analogously to Example 1, by debenzylation of 16 g of crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethyl]benzylamino]-3-[4-(carbamoylmethoxy)phenoxy]propan-2-ol,after crystallisation from dioxan the pure1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-[4-(carbamoylmethoxy)phenoxy]propan-2-olhaving a melting point of 145°-149° is obtained (sinters at atemperature of 140°) (mixture of the diastereoisomers).

EXAMPLE 16

Analogously to Example 3, by debenzylation of 18 g of crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylbenzylamino]-3-[2-[N'-(2-hydroxyethyl)ureidomethyl]phenoxy]propan-2-ol,after crystallisation from dimethylformamide/ether1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-[N'-(2-hydroxyethyl)ureidomethyl]phenoxy]propan-2-olis obtained having a melting point of 164°-166°.

The starting material can be prepared as follows:

2-benzyloxybenzylamine

In a Soxhlet apparatus 18.4 g of lithium aluminium hydride in 1800 ml ofdry ether are boiled under a nitrogen atmosphere at a bath temperatureof 70°, 5.3 g of 2-benzyloxybenzamide being introduced into the Soxhletthimble. After 21 hours the reaction mixture is immersed in an ice bath,and 18.4 ml of water, 18.4 ml of 15% sodium hydroxide solution and 55 mlof water are added dropwise in succession, whilst stirring. Thetemperature may be allowed to rise to a maximum of +10°. Stirring of themixture is then continued at 20° and the resulting precipitate issuction-filtered and washed with ether. The filtrate is concentrated byevaporation in vacuo and the oil remaining is stirred with 500 ml of 10%hydrochloric acid and 400 ml of ether for 2 hours, whilst cooling withice. The precipitated 2-benzyloxybenzylamine hydrochloride issuction-filtered, washed with water and ether and dried in vacuo.Melting point 190°-191°.

2 -benzyloxybenzyl isocyanate

38.5 g of 2-benzyloxybenzylamine hydrochloride are suspended in 400 mlof distilled toluene and heated at a bath temperature of 140°. Whilststirring, phosgene is introduced and after about 50 minutes the solutionbecomes clear. After a further 10 minutes, the addition of phosgene isinterrupted and boiling is continued for a further hour. The solution isthen left to cool a little and the toluene is distilled off in vacuo. Asample of the oil remaining was distilled in a bulb tube: Boiling point,bath temperature 120°/0.06 torr.

N-(2-hydroxyethyl)-N'-(2-benzyloxybenzyl)urea

A solution of 73.6 g of crude 2-benzyloxybenzyl isocyanate in 120 ml ofmethylene chloride is added dropwise in the course of 50 minutes to asolution of 36.8 ml of ethanolamine in 370 ml of methylene chloride. Thereaction is slightly exothermic. After 2 hours the reaction solution iswashed three times with 200 ml of water each time and dried using sodiumsulphate. Methylene chloride is distilled off and the residue isrecrystallised from isopropanol. The resulting product melts at 92°-94°.

N-(2-hydroxyethyl)-N'-(2-hydroxybenzyl)urea

59.6 g of N-(2-hydroxyethyl)-N'-(2-benzyloxybenzyl)-urea are dissolvedin 600 ml of methanol and hydrogenated in the presence of 6 g ofPd/C-catalyst (5%). After 2 hours the hydrogenation ceases. The catalystis suction-filtered, and the filtrate concentrated by evaporation invacuo. The residue is recrystallised from 350 ml of ethyl acetate; thepure product melts at 100°-101°.

N-[2-(2,3-epoxypropoxy)benzyl]-N'-(2-hydroxyethyl)urea

A mixture of 29.2 g of N-(2-hydroxyethyl)-N'-(2-hydroxybenzyl)urea, 440ml of epichlorohydrin and 38.9 g of potassium carbonate is stirred for 6hours at 90°. The solids are then suction-filtered whilst hot, washedwith acetonitrile and the filtrate is concentrated by evaporation invacuo. The oil remaining crystallises when left to stand and isrecrystallised from 320 ml of ethyl acetate, with carbon treatment. Theresulting epoxide melts at 96°-99°.

1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)ethyl]benzylamino]-3-[2-[N'-(2-hydroxyethyl)ureidomethyl]phenoxy]propan-2-ol

A solution of 9.75 g of the above epoxide and 9.4 g ofN-[(3-carbamoyl-4-hydroxyphenoxy)ethyl]benzylamine in 100 ml ofisopropanol is stirred for 7 hours at a bath temperature of 95°. Thesolution is concentrated by evaporation in vacuo. The resulting crudeproduct can be subjected directly to hydrogenolysis.

EXAMPLE 17

A mixture of 10.2 g of [2-(2,3-epoxypropoxy)phenyl]-prop-2-ynyl ether,7.8 g of 5-(2-aminoethoxy)salicylamide and 25 ml of isopropanol isrefluxed for 1 hour whilst stirring. The residue remaining afterconcentrating the reaction mixture by evaporation is dissolved in 30 mlof ethyl acetate. The1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(prop-2-ynyloxy)phenoxy]-propan-2-olcrystallising out melts after recrystallisation from ethanol at140°-141°.

(17a) The 5-(2-aminoethoxy)salicylamide required as starting materialcan be prepared by debenzylation, using hydrogen in the presence of aPd/C-catalyst (5%), of the corresponding N-benzyl compound (analogouslyto Example (3b) in methanol; it melts at 140°.

EXAMPLE 18

Analogously to Example 17, by using the correspondingly substitutedepoxides, the following compounds are obtained:

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-cyanophenoxy)propan-2-ol,melting point 121°-124° (from ethanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-chlorophenoxy)propan-2-ol,melting point 140°-141° (from ethanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methylthioethoxy)phenoxy]propan-2-ol,which forms a hydrochloride, melting point 202°-204°, (from methanol),

1-(2-allylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-ol,the neutral fumarate of which melts at 165°-166° (from ethanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,melting point 157°-158° (from methanol),

1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-ol,melting point 147°-148° (from methanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methyl-4-methylthiophenoxy)propan-2-ol,melting point 139°-141° (from acetonitrile),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methyl-4-methylsulphinylphenoxy)propan-2-olwith double melting point 92° and 140°,

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methyl-1,2,4-thiadiazol-5-yloxy)propan-2-ol,after chromatography on silica gel, as an amorphous powder having amelting point of 132° after sintering.

EXAMPLE 19

3.09 g of 4-(2,3-epoxypropoxy)benzimidazol-2-one and 4.29 g of5-[2-(benzylamino)ethoxy]salicylamide are refluxed for 3 hours in 80 mlof isopropanol. The solvent is then removed under reduced pressure. ThecrudeN-[2-(4-hydroxy-3-carbamoylphenoxy)ethyl]-N-[3-(2-oxobenzimidazol-4-yloxy)-2-hydroxypropyl]-N-benzylamineremaining is dissolved in 80 ml of methanol, 3 ml of a 5N methanolichydrogen chloride solution are added thereto, and the whole is thenshaken with the addition of 0.8 g of Pd/C-catalyst (5%) in ahydrogenating apparatus under a hydrogen atmosphere. When the hydrogenabsorption corresponding to the calculated amount has ceased, thecatalyst is filtered off, and the filtrate is concentrated under reducedpressure. As the concentrate cools,4-[3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-2-hydroxypropoxy]benzimidazol-2-onehydrochloride crystallises, melting point 148°-152° (afterrecrystallisation from methanol).

EXAMPLE 20

By catalytic debenzylation of1-[N-[2-(4-carbamoyl-3-hydroxyphenoxy)ethyl-benzylamino]-3-[4-(2-methoxyethoxy)-phenoxy]propan-2-ol,analogously to Example 1 there is obtained1-[2-(4-carbamoyl-3-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olhaving a melting point of 151°-152° (from methanol).

The starting material is prepared as follows:

(20a) 16.2 g of2,3-dihydro-2,2-dimethyl-7-hydroxy-4H-1,3-benzoxazin-4-one are reactedanalogously to Example (3a) with 84 ml of 1,2-dibromomethane and yield2,3-dihydro-2,2-dimethyl-7-(2-bromoethoxy)-4H-1,3-benzoxazin-4-onehaving a melting point of 156°-158° (from isopropanol).

(20b) 53 g of2,3-dihydro-2,2-dimethyl-7-(2-bromoethoxy)-4H-1,3-benzoxazin-4-one and94 g of benzylamine are boiled for 3 hours whilst stirring. The reactionmixture is rendered alkaline with concentrated ammonia, and the organicphase is concentrated by evaporation at a maximum temperature of 50°.

The 4-[2-(benzylamino)ethoxy]salicylamide obtained in this manner formsan oil, the hydrochloride of which melts at 252°-254° (from methanol).

(20c) Analogously to Example (4a), using4-[2-(benzylamino)-ethoxy]salicylamide,1-[N-[2-(4-carbamoyl-3-hydroxyphenoxy)-ethyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olis obtained as an oil which is debenzylated in its crude state.

EXAMPLE 21

Analogously to Example 8, by debenzylation of crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)ethyl]benzylamino]-3-(4-benzyloxyphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(4-hydroxyphenoxy)propan-2-olhaving a melting point of 130°-131° (from isopropanol), and, using the4-carbamoyl-3-hydroxy isomer,1-[2-(4-carbamoyl-3-hydroxyphenoxy)ethylamino]-3-(4-hydroxyphenoxy)propan-2-olhaving a melting point of 148°-151° (from methanol) are obtained, thehydrochloride salt of which melts at 224°-226°.

(21a) The starting materials may be obtained by reactingbenzyl-[4-(2,3-epoxypropoxy)phenyl]ether with 5- or4-[2-(benzylamino)ethoxy]salicylamide respectively analogously toExample 8b.

EXAMPLE 22

Analogously to Example 13, using 6-(2-bromoethoxy)-salicylamide,1-[2-(2-carbamoyl-3-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olis obtained; melting point 176°-179° (from methanol).

(22a) The starting material may be prepared as follows:

A mixture of 23.0 g of 2,6-dihydroxybenzamide, 20.7 g of potassiumcarbonate and 28.2 g of 1,2-dibromoethane is refluxed, whilst stirring,for 2-3 hours in 300 ml of acetonitrile. The reaction mixture isfiltered whilst still warm, the filtrate concentrated by evaporation andthe residue recrystallised from a little methanol.6-(2-Bromoethoxy)salicylamide having a melting point of 120°-121° isobtained.

EXAMPLE 23

The solution of 2.24 g of 5-(2-amino-2-methylpropoxy)salicylamide in 30ml of dioxan is refluxed for 7 hours after the addition of 2.3 g of2-(2,3-epoxypropoxy)-benzonitrile, and then concentrated by evaporation.The residue is divided between 10 ml of 2N hydrochloric acid and 100 mlof ethyl acetate. The acidic aqueous phase is rendered alkaline withconcentrated ammonia solution, the base is extracted with ethyl acetateand the solvent is evaporated off, whereupon an oil is obtained fromwhich, by crystallisation from isopropanol and recrystallisation fromethyl acetate,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1,1-dimethylethylamino]-3-(2-cyanophenoxy)propan-2-olhaving a melting point of 125°-126° is obtained.

The starting material may be obtained as follows:

(23a) A mixture of 84.3 g of2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-one, 144.2 g ofmethanesulphonic acid (2-methyl-2-nitropropyl)ester and 121 g of drypotassium carbonate in 440 ml of diethylene glycol dimethyl ether isstirred for 9 hours in a bath at approximately 150°. The reactionmixture is cooled, poured into 4000 ml of water and extracted with 3000ml of ethyl acetate. The oil obtained by concentrating the organic phaseby evaporation is dissolved in 250 ml of dioxan, and approximately 750ml of 2N hydrochloric acid are added until the reaction mixture turnsacidic. The solution is maintained at 80°-100° for one and a half hours,then concentrated to half the volume under reduced pressure andextracted 3 times with 500 ml of ethyl acetate each time. The combinedorganic phases are washed with 200 ml of water, then with saturatedsodium carbonate solution and finally with saturated sodium chloridesolution, dried over magnesium sulphate and concentrated by evaporation.The dark brown oil obtained in this manner is chromatographed on 500 gof silica gel. By elution with ether crystalline5-(2-methyl-2-nitropropoxy)salicylamide having a melting point of145°-148° is obtained.

(23b) 11.5 g of 5-(2-methyl-2-nitropropoxy)salicylamide are hydrogenatedin 150 ml of methanol at 40°-50° and 80 bar over 5 g of Raney nickeluntil hydrogen absorption ceases. By filtration and concentration of thefiltrate by evaporation, crude 5-(2-amino-2-methylpropoxy)salicylamideis obtained, which, after standing for a relatively long period,crystallises from isopropanol and melts at 115°-117°.

EXAMPLE 24

A mixture of 50 ml of dioxan and 500 ml of concentrated ammonia solutionis added to 21.5 g of1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-(3-hydroxy-4-methoxycarbonylphenoxy)propan-2-ol.The reaction mixture is stirred for 1-2 hours, and as soon as it ishomogeneous, left to stand for 3 days at 20°-30°. By concentration byevaporation, 20 g of crude, crystalline1-(4-carbamoyl-3-hydroxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]propan-2-olis obtained as a diastereoisomeric mixture having a melting point of180°-190°. A hydrochloride is formed which melts at 238°-243° (fromethanol/methanol).

The starting material may be prepared in the following manner:

(24a) By refluxing 34 g of 2,4-dihydroxybenzoic acid methyl ester with185 g of epichlorohydrin and 35 g of potassium carbonate for 2 to 3hours, and chromatographing the crude product on 100 g of silica gel(elution with toluene), 4-(2,3-epoxypropoxy)salicylic acid methyl esterhaving a melting point of 53°-55° is obtained.

(24b) After 40 hours' boiling and working up analogously to Example(4a), 22.4 g of 4-(2,3-epoxypropoxy)salicylic acid methyl ester and 30 gof 5-(2-benzylaminopropoxy)-salicylamide in 200 ml of isopropanol yieldcrude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethyl]benzylamino]-3-(3-hydroxy-4-methoxycarbonylphenoxy)propan-2-olas a light-coloured foam which is further processed as a crude product.

(24c) A solution of 46 g of1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethyl]benzylamino]-3-(3-hydroxy-4-methoxycarbonylphenoxy)propan-2-olin 500 ml of methanol is hydrogenated with the addition of 5 g ofPd/C-catalyst (5%) under normal conditions until 1 equivalent ofhydrogen has been absorbed. The product, which has partiallycrystallised out, is dissolved in about 2000 ml of hot methanol and thecatalyst is filtered off. By concentrating the filtrate,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-(3-hydroxy-4-methoxycarbonylphenoxy)propan-2-olhaving a melting point of 168°-172° is obtained as a diastereoisomericmixture.

EXAMPLE 25

5.2 g of crude1-[N-[2-(3-carbamoyl-2-hydroxyphenoxy)-ethyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olare hydrogenated and worked up analogously to Example 4. Afterrecrystallisation from isopropanol,1-[2-(3-carbamoyl-2-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)-phenoxy]propan-2-olhaving a melting point of 125°-129° is obtained.

The starting material is prepared as follows:

(25a) 2,3-dihydroxybenzoic acid methyl ester is reacted in the presenceof potassium carbonate in acetonitrile with 1.1 equivalents of1-dibenzylamino-2-chloroethane for 18 hours at 82°. The crude3-(2-dibenzylaminoethoxy)-salicylic acid methyl ester obtained afterworking up is put to further use without further purification.

(25b) The compound obtained in accordance with Example (25a) isdissolved in methanol and, after the addition of palladium-on-carboncatalyst, is hydrogenated until 1.1 equivalents of hydrogen have beenabsorbed. The catalyst is filtered off, the solvent evaporated off, theresidue taken up in ethyl acetate, the organic phase washed with waterand concentrated by evaporation, after which the crude3-(2-benzylaminoethoxy)salicylic acid methyl ester is obtained as ahoney-coloured oil.

(25c) The product obtained in accordance with Example (25b) is stirredwith 10 times the amount by weight of concentrated ammonia, and whendissolution has occurred, is left to stand for 4 to 5 days at roomtemperature. The solution is then concentrated by evaporation, theresidue is divided between water and ethyl acetate, the organic phase isdried over magnesium sulphate and concentrated by evaporation, afterwhich 3-(2-benzylaminoethoxy)salicylamide is obtained as a yellowishoil.

(25d) By reacting 2.5 g of1-(2,3-epoxypropoxy)-4-(2-methoxyethoxy)benzene with 2.9 g of crude3-(2-benzylaminoethoxy)salicylamide obtained according to Example (25c),analogously to Example (4a),1-[N-[2-(3-carbamoyl-2-hydroxyphenoxy)ethyl]benzylamino]-3-[4-(2-methoxyethoxy)-phenoxy]propan-2-olis obtained as an oil which is further processed in this state.

EXAMPLE 26

A solution of 2.5 g of1-amino-3-[4-(2-methoxyethoxy)-phenoxy]propan-2-ol and 2.23 g of(2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazin-4-on-6-yloxy)acetaldehyde in20 ml of ethanol is refluxed for 3 hours. After cooling, 0.8 g of sodiumborohydride is added in portions, whilst stirring, and stirring iscontinued for a further 3-4 hours at room temperature.

By adding 2N hydrochloric acid, the excess sodium borohydride isdecomposed, the solution is then concentrated by evaporation, theresidue rendered alkaline with ammonia solution and extracted 3 timeswith 300 ml of ethyl acetate each time. By concentrating by evaporationthe combined ethyl acetate solutions dried over magnesium sulphate, abrown residue is obtained, from which, by repeated recrystallisationfrom isopropanol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olhaving a melting point of 157°-158° is obtained.

The starting material is prepared as follows:

(26a) A solution of 9.65 g of2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-one and 9.1 g ofallyl bromide in 150 ml of acetonitrile is refluxed for 5 hours, whilststirring, with the addition of 10.3 g of dry potassium carbonate. Thereaction mixture is filtered whilst warm, the filtrate is concentratedby evaporation and the remaining crystals are suction-filtered aftertrituration with ether. The crude2,3-dihydro-2,2-dimethyl-6-(1-propen-3-yloxy)-4H-1,3-benzoxazin-4-oneobtained in this manner melts at 137°-138°.

(26b) Approximately 20 mg of osmium tetroxide are added to a solution of4.7 g of2,3-dihydro-2,2-dimethyl-6-(1-propen-3-yloxy)-4H-1,3-benzoxazin-4-one ina mixture of 50 ml of dioxan and 15 ml of water whilst stirring. After15 minutes 8.6 g of sodium metaperiodate are added in portions, thetemperature rising to 45°. After 2 hours the reaction mixture isfiltered, the filtrate concentrated by evaporation and the residuedivided between 20 ml of water and 200 ml of ethyl acetate. The organicphase is separated off, dried over sodium sulphate and concentrated byevaporation, and the resulting oil is chromatographed on 100 g of silicagel. By elution with ethyl acetate and concentration by evaporation,(2,3-dihydro-2,2-dimethyl-4H-1,3-benzoxazin-4-on-6-yloxy)acetaldehydehaving a melting point of 153°-163° is obtained.

EXAMPLE 27

After the addition of 0.2 g of palladium-on-carbon catalyst, a solutionof 4.1 g of1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-olin 100 ml of methanol is hydrogenated under normal conditions until 1equivalent of hydrogen has been absorbed. By filtration andconcentration of the solution by evaporation, colourless crystals areobtained which melt at 142°-143° after recrystallisation from methanoland consist of1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-propoxyphenoxy)propan-2-ol.

EXAMPLE 28

Analogously to Example 8, using1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)ethyl]benzylamino]-3-(2-benzyloxyphenoxy)propan-2-olas starting material,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-hydroxyphenoxy)propan-2-olis obtained which forms a neutral fumarate having a melting point of178°-180° (from ethanol).

The starting material can be obtained analogously to (Example 8b) frombenzyl-[2-(2,3-epoxypropoxy)phenyl]ether and5-[2-(benzylamino)ethoxy]salicylamide.

EXAMPLE 29

Analogously to Example 4,

(a) from1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)ethyl]-benzylamino]-3-(3-carbamoyl-4-hydroxyphenoxy)propan-2-olthere is obtained1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-carbamoyl-4-hydroxyphenoxy)-propan-2-ol,melting point 212°-215°, (from methanol);

(b) from1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)ethyl]-benzylamino]-3-[4-(2-oxopropoxy)phenoxy[propan-2-olthere is obtained1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[4-(2-oxopropoxy)phenoxy]propan-2-ol,melting point 118°-120° (from acetonitrile).

EXAMPLE 30

Analogously to Example 17, the following compounds are obtained usingthe correspondingly substituted epoxides:

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-acetamidoethyl)phenoxy]propan-2-ol;melting point of the hydrochloride 223°-224° (from methanol),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(4-acetamidomethylphenoxy)propan-2-ol,melting point 173°-176° (from Methyl Cellosolve),

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(4-carbamoylmethylphenoxy)propan-2-ol,melting point 181°-182°, (from dimethylformamide/water).

EXAMPLE 31

A solution of 25 g of crude1-[N-[4-(3-carbamoyl-4-hydroxyphenoxy)butyl]benzylamino]-3-[4-(2-methoxyethoxy)-phenoxy]propan-2-olin 250 ml of methanol is hydrogenated and worked up analogously toExample 4. The resulting crystalline crude product is recrystallisedfrom isopropanol and yields1-[4-(3-carbamoyl-4-hydroxyphenoxy)butylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olhaving a melting point of 122°-124°.

The starting material is prepared as follows:

(31a) A suspension of 96.5 g of2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-one and 76 g ofpotassium carbonate in 300 ml of 1,4-dibromobutane is stirred for 5hours in a bath at 120°-130°. The reaction mixture is filtered and theexcess 1,4-dibromobutane is distilled off at about 1 torr. Thecrystalline residue is triturated with ether and suction-filtered. Inthis manner crude2,3-dihydro-2,2-dimethyl-6-(4-bromobutoxy)-4H-1,3-benzoxazin-4-onehaving a melting point of 139°-142°, which is sufficiently pure forfurther reaction, is obtained.

(31b) A mixture of 65.6 g of2,3-dihydro-2,2-dimethyl-6-(4-bromobutoxy)-4H-1,3-benzoxazin-4-one, 85 gof benzylamine and 100 ml of water is heated at 110°-120° for 1 hour,whilst stirring. Whilst cooling with ice, the reaction mixture is thenacidified with concentrated hydrochloric acid, a salt mixture of5-(4-benzylaminoethoxy)salicylamide crystallising out after a few hours.The base liberated therefrom by means of 20% ammonia is extracted withethyl acetate and the organic phase is evaporated off. The residue formsan oil which crystallises gradually, (melting point 103°-106°, sintersat a temperature of 86° and above).

(31c) A solution of 15.7 g of the compound obtained according to Example23b and 13.4 g of 1-(2,3-epoxypropoxy)-4-(2-methoxyethoxy)benzene isreacted analogously to (Example 4a) to give1-[N-[4-(3-carbamoyl-4-hydroxyphenoxy)-butyl]benzylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-oland is further processed in this state.

EXAMPLE 32

A mixture of 8.4 g of1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-oland 30 ml of n-butylamine is heated in a rotating closed vessel for 17hours at 160°-170°. After evaporating off the butylamine, a crystallineresidue is left which is recrystallised from methanol and yields1-[2-(3-N-n-butylcarbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olhaving a melting point of 118°-119°.

EXAMPLE 33

A mixture of 8.1 g of1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-propoxyphenoxy)propan-2-oland 50 ml of a 33% solution of methylamine in ethanol is reactedanalogously to Example 32 in a closed vessel.

By concentrating the resulting solution by evaporation, an oil isobtained which is neutralised by adding a 5N solution of hydrochloricacid in methanol. After adding ether until the solution starts turningturbid,1-[2-[3-(N-methylcarbamoyl)-4-hydroxyphenoxy]ethylamino]-3-(2-propoxyphenoxy)propan-2-olgradually crystallises out as a hydrochloride having a melting point of114°-116°.

In an analogous manner, using piperidine1-[2-[3-(N-piperidinocarbonyl)-4-hydroxyphenoxy]ethylamino]-3-(2-propoxyphenoxy)propan-2-olis obtained as a viscous oil, the IR- and ¹ H-NMR-spectra of which arein concordance with the assumed structure and the Rf-value of which is0,70 according to thin-layer-chromatography on silicagel using a mixtureof ethylacetate-ethanol-conc. ammonia 24:12:4 as the eluent.

EXAMPLE 34

7.3 g of 2-(2,3-epoxypropoxy)benzonitrile are added to a solution of 6.7g of 5-(4-aminobutoxy)salicylamide in 60 ml of dimethyl sulphoxide andthe mixture is stirred for 1 hour in a bath at 90°. The reaction mixtureis poured into 300 ml of water and extracted twice with 200 ml of ethylacetate each time. Working up analogously to Example 23 yields crude1-[4-(3-carbamoyl-4-hydroxyphenoxy)butylamino]-3-(2-cyanophenoxy)propan-2-olas a viscous oil, the IR- and ¹ H-NMR-spectra of which are inconcordance with the assumed structure and the Rf-value of which is 0,51according to thin-layer-chromatography on silicagel using a mixture ofethylacetate-ethanol-conc. ammonia 24:12:4 as the eluent.

5-(4-Aminobutoxy)salicylamide needed as starting material is obtained bycatalytic debenzylation of 5-[4-(benzylamino)butoxy]salicylamide inmethanol using a palladium-on-carbon catalyst (5%), melting point78°-81° (from ethanol).

EXAMPLE 35

A solution of 3.5 g of1-[2-(3-cyano-4-hydroxyphenoxy)-ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olin a mixture of 15 ml of concentrated hydrochloric acid and 20 ml ofdioxan is stirred for 15 hours at 20°-25°. The reaction mixture is thenconcentrated by evaporation and rendered alkaline with 10% aqueousammonia solution. The crude1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olwhich is precipitated after standing for a few hours is filtered off andrecrystallised from a mixture of dioxan/methanol (1:1). Melting point157°-158°.

1-[2-(3-cyano-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olneeded as starting material is obtainable in a manner analogous to themethod described in Example 13 from1-[4-(2-methoxyethoxy)-phenoxy]-3-aminopropan-2-ol and5-(2-bromoethoxy)-2-hydroxybenzonitrile. The crude product obtainedafter working up is put to further use in this state.

EXAMPLE 36

Tablets containing 20 mg of active substance are manufactured in thefollowing composition in the customary manner.

    ______________________________________                                        Composition:                                                                  ______________________________________                                        1-[2-(3-carbamoyl-4-hydroxyphenoxy)-                                                                   20     mg                                            ethylamino]-3-[4-(2-methoxyethoxy)- -phenoxy]propan-2-ol                      wheat starch             60     mg                                            lactose                  50     mg                                            colloidal silica         5      mg                                            talc                     9      mg                                            magnesium stearate       1      mg                                                                     145    mg                                            ______________________________________                                    

MANUFACTURE

1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olis mixed with part of the wheat starch, with the lactose and colloidalsilica and the mixture is pressed through a sieve. A further portion ofthe wheat starch is made into a paste using a water bath with 5 timesthe amount of water and the powder mixture is kneaded with this pasteuntil a slightly plastic composition has formed.

The plastic composition is pressed through a sieve having a mesh widthof approximately 3 mm, dried, and the resulting dry granulate is againpressed through a sieve. The remaining wheat starch, the talc andmagnesium stearate are then admixed and the mixture is compressed toform tablets of 145 mg weight having a breaking groove.

EXAMPLE 37

Tablets containing 1 mg of active substance are manufactured in thefollowing composition in the customary manner:

    ______________________________________                                        Composition:                                                                  ______________________________________                                        1-(4-hydroxyphenoxy)-3-[2-(3-carbamoyl-                                                                 1       mg                                          4-hydroxyphenoxy)-1-methylethylamino]propan-                                  2-ol                                                                          wheat starch              60      mg                                          lactose                   50      mg                                          colloidal silica          5       mg                                          talc                      9       mg                                          magnesium stearate        1       mg                                                                    126     mg                                          ______________________________________                                    

MANUFACTURE

1-(4-Hydroxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]propan-2-olis mixed with part of the wheat starch, with the lactose and colloidalsilica and the mixture is pressed through a sieve. A further portion ofthe wheat starch is made into a paste using a water bath with 5 timesthe amount of water, and the powder mixture is kneaded with this pasteuntil a slightly plastic composition has formed.

The plastic composition is pressed through a sieve having a mesh widthof approximately 3 mm, dried, and the resulting dry granulate is againpressed through a sieve. The remaining wheat starch, the talc andmagnesium stearate are then admixed, and the mixture is compressed toform tablets of 145 mg weight having a breaking groove.

EXAMPLE 38

Capsules containing 10 mg of active substance are manufactured in thecustomary manner as follows:

    ______________________________________                                        Composition:                                                                  ______________________________________                                        1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-                                                              2500   mg                                           hydroxyphenoxy)ethylamino]propan-2-ol                                         talc                      200    mg                                           colloidal silica          50     mg                                           ______________________________________                                    

MANUFACTURE

The active substance is intimately mixed with the talc and colloidalsilica, the mixture is pressed through a sieve having a mesh width of0.5 mm, and introduced in 11 mg portions into hard gelatin capsules ofsuitable size.

EXAMPLE 39

A sterile solution of 5.0 g of1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olmethane sulphonate in 5000 ml of distilled water is introduced into 5 mlampoules which contain 5 mg of active substance in 5 ml of solution.

EXAMPLE 40

3.62 g of1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(4-hydroxyphenoxy)propan-2-olare dissolved, with the addition of 100.0 ml of 0.10N hydrochloric acid,in 18000 ml of distilled water to a volume of 18100 ml. The sterilisedsolution is introduced into 5.0 ml ampoules containing 1 mg of activesubstance.

EXAMPLE 41

Instead of the compounds used as the active substances in Examples 36 to40, the following compounds of the formula I, or the pharmaceuticallyacceptable non-toxic acid addition salts thereof, may also be used asactive substances in tablets, dragees, capsules, ampoule solutions etc.:

1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,1-[2-(4-carbamoyl-3-hydroxyphenoxy)-1-methylethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-[N-(2-hydroxyethyl)-carbamoylmethoxy]phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-phenoxypropan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-[2-(methoxycarbonyl)ethoxy]phenoxy]propan-2-ol,1-(4-acetamidophenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-methylphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methylphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-methylindol-4-yloxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-(trifluoromethylphenoxy)propan-2-ol,1-(2-acetylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-ol,1-[4-[2-(acetamido)ethoxy]phenoxy]-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methylpyridin-2-yloxy)propan-2-ol,5-[3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-cis-naphthalenediol,4-[2-hydroxy-3-[(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propoxy]phenylacetamide,4-[2-hydroxy-3-[(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]propoxy]phenoxyacetamide,N-[4-[2-hydroxy-3-[(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propoxy]-phenyl]-N',N'-dimethylurea,1-(4-butyroylamino-2-acetylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-methoxyphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2,3-dimethylphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[3-(2-methoxyethoxy)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(pyrrol-1-yl)phenoxy]-propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methyl-4-methylsulphonylphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(1-naphthyloxy)-propan-2-ol,5-[3-[2-(4-carbamoyl-3-hydroxyphenoxy)-1-methylethylamino]-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone,1-[3-(3-carbamoyl-4-hydroxyphenyl)propylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-(4-methylcarbamoylphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol,1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-cyanophenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(prop-2-ynyloxy)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methylthioethoxy)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-allylphenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]-3-[4-(carbamoylmethoxy)-phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[2-[N'-(hydroxyethyl)ureidomethyl]phenoxy]-propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(prop-2-nyloxy)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-cyanophenoxy)-propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-chlorophenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methylthioethoxy)-phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-(methyl-4-methylthiophenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methyl-4-methylsulphinylphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methyl-1,2,4-thiadiazol-5-yloxy)propan-2-ol,4-[3-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-2-hydroxypropoxy]benzimidazol-2-onehydrochloride,1-[2-(4-carbamoyl-3-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,1-[2-(2-carbamoyl-3-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)-phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1,1-dimethylethylamino]-3-[4-(methylcarbamoyl)phenoxy]-propan-2-ol,1-(4-carbamoyl-3-hydroxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]propan-2-olas a diastereoisomeric mixture,1-[2-(3-carbamoyl-2-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]-propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-propoxyphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-hydroxyphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-carbamoyl-4-hydroxyphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-carbamoylphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-oxopropoxy)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino[4-3-[-(2-acetamidoethyl)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[4-(acetamidomethyl)phenoxy]propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(4-carbamoylmethylphenoxy)propan-2-ol,1-[4-(3-carbamoyl-4-hydroxyphenoxy)butylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,1-[2-[3-(N-n-butylcarbamoyl)-4-hydroxyphenoxy]ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-ol,1-[2-[3-(N-methylcarbamoyl)-4-hydroxyphenoxy]ethylamino]-3-(2-propoxyphenoxy)propan-2-ol,1-[4-(3-carbamoyl-4-hydroxyphenoxy)butylamino]-3-(2-cyanophenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(2-methoxy-ethoxy)phenoxy]propan-2-ol,1-(2-carbamoylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]propan-2-ol,1-[2-(4-carbamoyl-3-hydroxyphenoxy)ethylamino]-3-(4-hydroxyphenoxy)propan-2-ol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[2-(2,3-dihydroxypropyl)-phenoxy]-2-propanol,1-[2-(4-carbamoyl-3-hydroxyphenoxy)-1-methylethylamino]-3-(methansulphonylaminophenoxy)-2-propanol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[4-[2-(cyclopropylmethoxy)-ethyl]-phenoxy]-2-propanol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-(4-methanesulphonylamino-phenoxy)-2-propanol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methyl-ethylamino]-3-(4-methanesulphonylamino-phenoxy)-2-propanol,1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[4-(N-methyl-methanesulphonylamino)-phenoxy]-2-propanolor4-[3-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-2-hydroxy-propoxy]-N-methylcinnamicacid amide.

EXAMPLE 42

A solution of 6.9 g of1-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]-3-[2-(2,2-dimethyl-dioxolan-4-yl)-methyl]-phenoxy]-2-propanolin 165 ml of 0.1N hydrochloric acid is left to stand at 20° for 5 hours.It is then washed twice with ether; the aqueous phase is filtered, andis subsequently concentrated in vacuo with a bath-temperature of 40°.The aqueous solution obtained is lyophilised to yield1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-3-[2-(2,3-dihydroxy-propyl)-phenoxy]-2-propanolhydrochloride in the form of colourless amorphous powder.

The starting material can be produced in the following manner:

(a) A mixture of 76.8 g of4-(2-hydroxybenzyl)-2,2-dimethyl-1,3-dioxolane, 248 ml ofepichlorohydrin and 69.7 g of potassium carbonate is stirred for 7 hoursat a bath-temperature of 130°.

The reaction mixture is filtered, and concentrated in vacuo to dryness.The residue is dissolved in ether; the solution is washed with 2N sodiumhydroxide solution and then with water; it is dried over sodium sulfateand subsequently concentrated by evaporation. The resulting crude4-[2-(2,3-epoxy-propoxy)-benzyl]-2,2-dimethyl-1,3-dioxolane is furtherprocessed as such.

(b) A mixture of 17.4 g of the crude compound obtained and 17.1 g of5-(2-benzylamino-ethoxy)-salicylamide in 60 ml of dimethyl sulfoxide isstirred for 20 hours at a bath-temperature of 80°. The reaction mixtureis poured into ice and water, and extracted with ethyl acetate. Theorganic phase is diluted with ether, and successively washed with 0.1Nhydrochloric acid (at pH 4-5) and then with aqueous saturated potassiumcarbonate solution, and dried over sodium sulfate. Concentration byevaporation leaves an oil, which is chromatographed through silica gelwith methylene chloride/methanol. Further processing yields1-[N-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethyl]-benzyl-amino]-3-[2-[(2,2-dimethyl-dioxolan-4-yl)-methyl]-phenoxy]-2-propanolas thick oil.

(c) A solution of 23.5 g of the resulting compound in 240 ml of methanolis hydrogenated with the addition of 2.4 g of palladium-on-charcoalcatalyst under normal conditions. The reaction product is dissolved inethyl acetate, and precipitated in crystalline form by the addition ofpetroleum ether. The crystals are again dissolved in ethyl acetate, andthe solution is stirred with 4.5 g of silica gel for 1/2 hour. Petroleumether is added portionwise to the filtrated solution to thus obtain1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-3-[2-[(2,2-dimethyl-dioxolan-4-yl)-methyl]-phenoxy]-2-propanol,m.p. 91°-93°.

EXAMPLE 43

A solution of 20.0 g of crude1-[N-[2-(4-carbamoyl-3-hydroxy-phenoxy)-1-methyl-ethyl]-benzylamino]-3-(4-methane-sulfonylamino-phenoxy)-2-propanolin 250 ml of methanol is hydrogenated, after the addition of 2.5 g ofPd/C catalyst (5%), under normal conditions until debenzylation iscompleted (DC control), for which an addition of a further 1.0 g ofcatalyst is required. The catalyst is filtered off; the filtrate isconcentrated by evaporation, and the oil remaining behind is dissolvedin a small amount of hot isopropanol. On cooling is obtained crystalline1-[2-(4-carbamoyl-3-hydroxy-phenoxy)-1-methyl-ethylamino]-3-(4-methanesulfonylamino-phenoxy)-2-propanol,m.p. 147°-150° (diastereoisomeric mixture).

The starting material is obtained in the following manner:

(43a) According to the method described by Irvine et al., Synthesis1972, 568, 2,4-dihydroxybenzamide is converted, using an excess ofacetone, into2,3-dihydro-2,2-dimethyl-7-hydroxy-4H-1,3-benzoxazin-4-one, m.p.249°-251°.

(43b) From 168 g of2,3-dihydro-2,2-dimethyl-7-hydroxy-4H-1,3-benzoxazin-4-one, 305 g ofpotassium carbonate and 88 ml of chloroacetone in 1.2 liters ofacetonitrile is obtained, by boiling for 28 hours and subsequentprocessing,2,3-dihydro-2,2-dimethyl-7-(2-oxo-propoxy)-4H-1,3-benzoxazin-4-one, m.p.160°-162° (from isopropanol).

(43c) A solution of 75 g of crude2,3-dihydro-2,2-dimethyl-7-(2-oxo-propoxy)-4H-1,3-benzoxazin-4-one and32 g of benzylamine in 1000 ml of methanol is hydrogenated, with theaddition of 0.75 g of conc. sulfuric acid and 1.6 g of a Pt/C catalyst(5%), under normal condition until the absorption of hydrogen hasceased. After removal of the catalyst by filtration and of the solventby evaporation, the oily residue is distributed between 300 ml of ethylacetate and 500 ml of 2N hydrochloric acid. There is then isolated fromthe aqueous phase, by rendering alkaline with concentrated ammonia(ice-cooling) and extracting with ethyl acetate, crude2,3-dihydro-2,2-dimethyl-7-[(2-benzylamino)-propoxy]-4H-1,3-benzoxazin-4-onein the form of oil, which can be further processed in the crude state.

(43d) A mixture of 100 g of crude2,3-dihydro-2,2-dimethyl-7-[(2-benzylamino)-propoxy]-4H-1,3-benzoxazin-4-one,100 ml of isopropanol and 100 ml of isopropylamine is refluxed for 1hour, and then concentrated by evaporation. The oil remaining behindcrystallises on trituration with ether. The crystals are filtered offwith suction, and washed with a small amount of isopropanol to thusyield 4-[2-(benzylamino)-propoxy]-salicylamide, m.p. 121°-123°.

(43e) A solution of 19.0 g of 4-[2-(benzylamino)-propoxy]-salicylamideand 12.4 g of 4-(2,3-epoxypropoxy)-nitrobenzene in 300 ml of isopropanolis refluxed for 20 hours. After the addition of a further 1.2 g of4-(2,3-epoxypropoxy)-nitrobenzene, refluxing is continued for a further20 hours. The solvent is subsequently partially evaporated off,whereupon1-[N-[2-(4-carbamoyl-3-hydroxy-phenoxy)-1-methyl-ethyl]-benzylamino]-3-(4-nitrophenoxy)-2-propanol,m.p. 160°-164° (diastereoisomeric mixture) crystallises out.

(43f) A solution of 19.0 g of the resulting compound in 380 ml ofdioxane is hydrogenated, with the addition of 18 g of Raney nickel in 4portions, under normal conditions, until 3 mol-equivalents of hydrogenhave been absorbed. After filtration and subsequent concentration byevaporation of the filtrate, there remains behind crude1-[N-[2-(4-carbamoyl-3-hydroxy-phenoxy)-1-methyl-ethyl]-benzylamino]-3-(4-amino-phenoxy)-2-propanolin the form of orange-brown oil, which can be further processed withoutadditional purification.

(43g) 16 g of the compound obtained are dissolved in 90 ml of anhydrouspyridine, and to the solution are added dropwise, with cooling to5°-10°, 4.4 g of methanesulfonic acid chloride. The reaction mixture isstirred for 4 hours at room temperature; the solvent is then evaporatedoff, and the residue is distributed between 400 ml of ethyl acetate and50 ml of water. The organic phase is washed three times with 50 ml ofwater each time and dried over magnesium sulfate; it is subsequentlytreated with charcoal, and concentrated by evaporation to yield crude1-[N-[2-(4-carbamoyl-3-hydroxy-phenoxy)-1-methyl-ethyl]-benzylamino]-3-(4-methanesulfonylamino-phenoxy)-2-propanolin the form of orange-coloured oil, which can be further processedwithout additional purification.

EXAMPLE 44

A solution of 30 g of crude1-[N-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethyl]-benzylamino]-3-[4-[2-(cyclopropylmethoxy)-ethyl]-phenoxy]-2-propanolin 600 ml of methanol is hydrogenated, with the addition of 4 g of aPd/C catalyst (5%), under normal conditions until 1 mol-equivalent ofhydrogen has been absorbed. By the addition of dioxane and by heating,the product which has already crystallised out is taken into solution;the catalyst is filtered off and the filtrate is concentrated byevaporation. Recrystallisation from isopropanol and then from methanolyields pure1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-3-[4-[2-(cyclopropylmethoxy)-ethyl]-phenoxy]-2-propanol,m.p. 149°-150°.

The starting material is produced in the following manner:

(44a) By application of the method described by Irvine et al., Synthesis1972, 568, 2,5-dihydroxy-benzamide is converted, using an excess ofacetone, into2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-one, m.p.215°-216°.

(44b) 70 g of 2,3-dihydro-2,2-dimethyl-6-hydroxy-4H-1,3-benzoxazin-4-onein 400 ml of acetonitrile with 100 g of potassium carbonate and 32 ml ofchloroacetone are stirred under reflux for 30 hours. After the additionof a further 3.2 ml of chloroacetone, the reaction mixture is refluxedfor a further 15-20 hours. The reaction mixture is filtered whilst stillwarm; the residue is thoroughly washed with acetone, and the combinedfiltrate is concentrated by evaporation. The crystalline residue isrecrystallised from toluene and yields2,3-dihydro-2,2-dimethyl-6-(2-oxopropoxy)-4H-1,3-benzoxazin-4-one, m.p.125°-126°.

(44c) 74 g of the resulting2,3-dihydro-2,2-dimethyl-6-(2-oxo-propoxy)-4H-1,3-benzoxazin-4-one in amixture of 150 ml of dioxane and 450 ml of 2N hydrochloric acid areheated for 45 minutes on a water bath. The solvent is evaporated off,and the crystalline residue is triturated with water and then filteredoff with suction. Recrystallisation from isopropanol yields5-(2-oxo-propoxy)-salicylamide, which has a melting point of 152°-154°.

(44d) 55 g of benzylamine and 1.25 g of conc. sulfuric acid are added toa solution of 104.5 g of 5-(2-oxo-propoxy)-salicylamide in 1000 ml ofmethanol, and the mixture is hydrogenated, in the presence of 3.0 g of aPt/C catalyst under normal conditions until 1 equivalent of hydrogen hasbeen absorbed. The catalyst is filtered off, and the solution is thenstirred up with about 10 g of pulverised calcium carbonate; the mixtureis again filtered, and concentrated by evaporation. The oil remainingbehind crystallises from isopropanol. Repeated recrystallisation fromisopropanol yields 5-[2-(benzylamino)-propoxy]-salicylamide, m.p.102°-104°.

(44e) A solution of 14.3 g of1-[2-(cyclopropyl-methoxy)-ethyl]-4-(2,3-epoxypropoxy)-benzene (GermanOffenlegungsschrift No. 2,649,605) and 16.3 g of5-[2-(benzylamino)-propoxy]-salicylamide in 200 ml of isopropanol isrefluxed for 18 hours. The reaction mixture is concentrated byevaporation to leave crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethyl]-benzylamino]-3-[4-[2-(cyclopropylmethoxy)-ethyl]-phenoxy]-2-propanolin the form of brown oil, which can be further processed withoutadditional purification.

EXAMPLE 45

The following compounds are prepared in a manner analogous to Example43:

1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-3-(4-methanesulphonylamino-phenoxy)-2-propanol;

1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-1-methyl-ethylamino]-3-(4-methanesulphonylamino-phenoxy)-2-propanol.

EXAMPLE 46

A mixture of 11.5 g of 4-(2,3-epoxy-propoxy)-cinnamic acid-N-methylamideand 7.4 g of 5-(2-aminoethoxy)-salicylamide is dissolved in 50 ml ofdimethyl sulfoxide heated to about 80°; the solution is stirred for 1hour at 75°-85°, and is then poured into 500 ml of water. The resinousproduct which precipitates is separated and stirred up with 150 ml ofethyl acetate. The precipitating crystals are filtered off with suction,and recrystallised from a small amount of isopropanol to thus obtain4-[3-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-2-hydroxypropoxy]-N-methylcinnamicacid amide, m.p. 170°-171° (sinters from 148°).

EXAMPLE 47

A solution of 41 g of crude1-[N-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethyl]-benzylamino]-3-[4-N-methyl-methanesulfonylamino)-phenoxy]-2-propanolin 410 ml of methanol is hydrogenated, in a manner analogous to thatdescribed in Example 4, in the presence of 4 g of palladium-on-charcoalcatalyst and subsequently processed. The product obtained afterrecrystallisation from ethanol and methanol is1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-3-[4-(N-methyl-methanesulphonylamino)-phenoxy]-2-propanol,m.p. 120°-121°.

The starting material is produced in the following manner:

(47a) 77 ml of methanesulfonic acid chloride are added dropwise in thecourse of about 30 minutes, with ice-cooling and stirring, to a solutionof 103.7 g of 4-methylaminophenol sulfate in 330 ml of pyridine and 102ml of N,N-diisopropylethylamine, and the mixture is stirred overnight atroom temperature. The volatile constituents are evaporated off, and theresidue is distributed between ethyl acetate and water; the organicphase is subsequently separated and concentrated by evaporation, and thecrystalline residue is heated with 300 ml of 6N sodium hydroxidesolution on a water-bath until completely dissolved. The solution isfiltered, and the pH-value is adjusted to 2 with concentratedhydrochloric acid, whereupon 4-(N-methylsulfonylamino)-phenolprecipitates in crystalline form. It is filtered off with suction anddried in vacuo at 80°, m.p. 135°-136°.

(47b) A mixture of 34.2 g of the compound obtained according to Example(47a) 35.2 g of potassium carbonate and 125 ml of epichlorohydrin isstirred and refluxed for 2 hours. The suspension is filtered, thefiltrate is concentrated by evaporation and distributed between ethylacetate and water; the organic phase is then separated, dried overmagnesium sulfate, and concentrated by evaporation to thus obtain4-(2,3-epoxy-propoxy)-N-methylmethanesulfonanilide, m.p. 96°-100° (frommethanol).

(47c) A solution of 19.0 g of the compound obtained according to Example(47b) and 21.4 g of 5-(2-benzylaminoethoxy)-salicylamide in 350 ml ofisopropanol is refluxed for 5 hours. The product obtained afterconcentrating by evaporation is crude1-[N-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethyl]-benzylamino]-3-[4-(N-methyl-methanesulfonylamino)-phenoxy]-2-propanolin the form of viscous oil, which is further processed as such.

What is claimed is:
 1. A compound of the formula ##STR32## in which Aris unsubstituted or substituted phenyl, naphthyl,1,2,3,4-tetrahydro-5-naphthyl, pyridyl, pyridazinyl, pyrimidinyl,pyrazinyl, thienyl, thiazolyl, thiadiazolyl, indolyl, quinolinyl,isoquinolinyl,[3,4-dihydro-2-(1H)-quinolinolyl,][2-oxo-benzimidazol-4-yl,]naphthyridinylor benzofuranyl, and where said group Ar is substituted there are one orat most three substituents selected from lower alkyl, lower alkenyl orlower alkoxy, lower alkenyloxy, lower alkynyl, lower alkynyloxy, cyanoand/or nitro, and/or, as substituents bonded directly or to theabove-mentioned lower alkyl, lower alkenyl or lower alkoxy, one or moreof lower alkanoyl, cycloalkyl, lower alkoxycarbonyl, carbamoyl, loweralkylcarbamoyl, di-lower alkylcarbamoyl or (hydroxy-loweralkyl)-carbamoyl, lower alkylsulphinyl, lower alkylsulphonyl, sulphamoylor lower alkylsulphamoyl; or halogen bonded directly to said group Ar,or halogen bonded to said lower alkyl or, in a position higher than the1-position, halogen bonded to said lower alkoxy; or hydroxy, bondeddirectly or bonded to said lower alkyl; as substituents not bondeddirectly to said group Ar, lower alkoxy, cycloalkyl-lower alkoxy,phenyl-lower alkoxy, lower alkanoyloxy, lower alkylthio, amino, loweralkylamino, di-lower alkylamino, alkyleneamino or oxa-alkyleneamino,pyrrol-1-yl, lower alkanoylamino, lower alkoxycarbonylamino, ureido,ureido substituted by one or two lower alkyl, by hydroxy-lower alkyl orby cycloalkyl or lower alkylsulphonylamino, n is the number 0 or 1; alkis alkylene having from 2 to 4 carbon atoms, the nitrogen atom and theoxygen atom or, if n is zero, the phenyl radical being separated fromone another by 2 or 3 carbon atoms, and R₁ and R₂ independentlyrepresent hydrogen or lower alkyl, or together represent piperidino, orpharmaceutically acceptable, non-toxic acid addition salts thereof. 2.Compounds of the formula I, according to claim 1, in which Ar representsphenyl, naphthyl or 1,2,3,4-tetrahydro-5-naphthyl, which radicals may beunsubstituted or substituted one to three times, wherein as substituentsthere may be present, optionally substituted in the manner specifiedhereinafter, lower alkyl, lower alkenyl or lower alkoxy, also loweralkenyloxy, lower alkynyloxy, and/or cyano and/or as substituents bondeddirectly or to the above-mentioned lower alkyl, lower alkenyl or loweralkoxy, one or more of lower alkanoyl, cycloalkyl, lower alkoxycarbonyl,carbamoyl, lower alkylcarbamoyl or (hydroxy)-lower alkyl carbamoyl,lower alkylsulphinyl, lower alkylsulphonyl, sulphamoyl or loweralkylsulphamoyl; and/or halogen bonded directly or halogen bonded to theabove-mentioned lower alkyl or, in a position higher than the1-position, halogen bonded to the above-mentioned lower alkoxy; hydroxy,hydroxy-lower alkyl or polyhydroxy-lower alkyl; or, as substituent notdirectly bonded, again lower alkoxy, cycloalkyl-lower alkoxy, alsophenyl-lower alkoxy, lower alkanoyloxy, lower alkylthio, amino, loweralkylamino, di-lower alkylamino, alkyleneamino or oxa-alkyleneamino,pyrrol-1-yl, lower alkanoylamino or lower alkoxycarbonylamino, ureidooptionally substituted by lower alkyl or cycloalkyl, or loweralkylsulphonylamino; and in which n represents the number 0 or 1, alkrepresents an alkylene radical having from 2 to 4 carbon atoms, thenitrogen atom and the oxygen atom, or if n is 0, the phenyl radical,being separated from one antoher by 2 or 3 carbon atoms, and R₁ and R₂independently of one another each represents hydrogen or lower alkyl,and salts, pharmaceutically acceptable, non-toxic acid addition saltsthereof.
 3. Compounds of the formula I, according to claim 1, in whichAr represents phenyl which may be unsubstituted or substituted one tothree times, wherein as substituents there may be present, optionallysubstituted in the manner specified hereinafter, lower alkyl or loweralkoxy, also lower alkenyl, lower alkenyloxy, lower alkynyloxy, and/orcyano and/or, as substituents bonded directly or to the above-mentionedlower alkyl or lower alkoxy, one or more of lower alkanoyl, cycloalkyl,lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl or (hydroxy)-loweralkyl carbamoyl, lower alkylsulphinyl, lower alkylsulphonyl; and/orhalogen bonded directly or halogen bonded to the above-mentioned loweralkyl or, in a position higher than the 1-position, halogen bonded tothe above-mentioned lower alkoxy; hydroxy, hydroxy-lower alkyl orpolyhydroxy-lower alkyl, or, as substituent not directly bonded, againlower alkoxy, cycloalkyl-lower alkoxy, also phenyl-lower alkoxy, loweralkylthio, alkyleneamino or oxa-alkyleneamino, pyrrol-1-yl, loweralkanoylamino or lower alkoxycarbonylamino, or ureido optionallysubstituted by lower alkyl, or lower alkylsulphonylamino; and in which nrepresents the number 0 or 1, alk represents an alkylene radical havingfrom 2 to 4 carbon atoms, the nitrogen atom and the oxygen atom, or, ifn is 0, the phenyl radical, being separated from one another by 2 or 3carbon atoms, and R₁ and R₂, independently of one another, eachrepresents hydrogen or lower alkyl, and pharmaceutically acceptable,non-toxic acid addition salts thereof.
 4. Compounds of the formula I,according to claim 1, in which Ar represents phenyl which may beunsubstituted or substituted one to three times, wherein as substituentsthere may be present, optionally substituted in the manner specifiedhereinafter, lower alkyl or lower alkoxy, also lower alkenyl, loweralkenyloxy, lower alkynyloxy, and/or cyano, and/or as substituentsbonded directly or to the above-mentioned lower alkyl or lower alkoxy,one or more of lower alkanoyl, cycloalkyl, carbamoyl, loweralkylcarbamoyl or (hydroxy)-lower alkyl carbamoyl, lower alkylsulphinyland lower alkylsulphonyl; and/or fluorine or chlorine bonded directly orto the above-mentioned lower alkyl or in a position higher than the1-position, to the above-mentioned lower alkoxy; hydroxy, hydroxy-loweralkyl or 1,2-dihydroxy or 2,3-dihydroxy-lower alkyl such as2,3-dihydroxypropyl, or, as substituent not directly bonded, again loweralkoxy, cycloalkyl-lower alkoxy, also phenyl-lower alkoxy, loweralkylthio, pyrrol-1-yl, lower alkanoylamino, lower alkoxycarbonylamino,ureido or lower alkylsulphonylamino such as N-methylmethylsulfonylamino, and in which n represents the integer 1, alkrepresents an alkylene radical having from 2 to 4 carbon atoms, thenitrogen atom and the oxygen atom being separated from one another by 2carbon atoms, and R₁ and R₂ represent hydrogen, and pharmaceuticallyacceptable, non-toxic acid addition salts thereof.
 5. Compounds of theformula I according to claim 1, in which the phenyl radical carrying theamide and the hydroxy group is bonded in its 4-position, or in its5-position, to the remainder of the molecule, and pharmaceuticallyacceptable, non-toxic acid addition salts thereof.
 6. A compound asclaimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.7. A compound as claimed in claim 1 which is1-(4-hydroxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-1-methylethylamino]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.8. A compound as claimed in claim 1 which is1-(2-allyloxyphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.9. A compound as claimed in claim 1 which is1-[4-[2-(acetamido)ethoxy]phenoxy]-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.10. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(2-oxopropoxy)-phenoxy]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.11. A compound as claimed in claim 1 which is1-[2-(4-carbamoyl-3-hydroxyphenoxy)-1-methylethylamino]-3-[4-(2-methoxyethoxy)phenoxy]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.12. A compound as claimed in claim 1 which is4-[2-hydroxy-3-[(3-carbamoyl-4-hydroxyphenoxy)-ethylaminopropoxy]phenylacetamideor a pharmaceutically acceptable non-toxic acid addition salt thereof.13. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-[2-(methoxycarbonylamino)ethoxy]phenoxy]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.14. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methyl-4-methylsulphinylphenoxy)propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.15. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-cyanophenoxy)propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.16. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-propoxyphenoxy)propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.17. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(pyrrol-1-yl)-phenoxy]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.18. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hyroxyphenoxy)ethylamino]-3-[2-(2-propynyloxy)-phenoxy]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.19. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-methoxyphenoxy)-propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.20. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(2-methylindol-4-yloxy)propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.21. A compound as claimed in claim 1 which is1-(2-acetylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.22. A compound as claimed in claim 1 which is5-[3-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-cis-naphthalenediol or a pharmaceutically acceptable non-toxic acid addition saltthereof.
 23. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-(3-methylphenoxy)-propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.24. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[2-(2-methoxyethoxy)phenoxy]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.25. A compound as claimed in claim 1 which is1-(2-carbamoylphenoxy)-3-[2-(3-carbamoyl-4-hydroxyphenoxy)-ethylamino]propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.26. A compound as claimed in claim 1 which is1-[2-(4-carbamoyl-3-hydroxyphenoxy)ethylamino]-3-(4-hydroxyphenoxy)-propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.27. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-3-[2-(2,3-dihydroxypropyl)-phenoxy]-2-propanolor a pharmaceutically acceptable non-toxic acid addition salt thereof.28. A compound as claimed in claim 1 which is1-[2-(4-carbamoyl-3-hydroxy-phenoxy)-1-methyl-ethylamino]-3-(4-methanesulphonylaminophenoxy)-2-propanolor a pharmaceutically acceptable non-toxic acid addition salt thereof.29. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-3-[4-[2-(cyclopropylmethoxy)-ethyl]-phenoxy]-2-propanolor a pharmaceutically acceptable non-toxic acid addition salt thereof.30. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-ethylamino]-3-(4-methanesulphonylamino-phenoxy)-2-propanolor a pharmaceutically acceptable non-toxic acid addition salt thereof.31. A compound as claimed in claim 1 which is1-[2-(3-carbamoyl-4-hydroxy-phenoxy)-1-methyl-ethylamino]-3-(4-methanesulphonylamino-phenoxy)-2-propanolor a pharmaceutically acceptable non-toxic acid addition salt thereof.32. A compound according to claim 1 which is1-[2-(3-carboamoyl-4-hydroxyphenoxy)ethylamino]-3-(4-hydroxyphenoxy)propan-2-olor a pharmaceutically acceptable non-toxic acid addition salt thereof.33. A pharmaceutical composition useful in the treatment of anginapectoris, cardiac arrhytmia as well as mycocardial insufficiency and asblood-pressure reducing agent comprising a therapeutically effectiveamount of a compound of formula I as defined in claim 1, or apharmaceutically acceptable non-toxic acid addition salt thereoftogether with a pharmaceutically acceptable excipient.
 34. Apharmaceutical composition useful in the treatment of reactive orendogenic states of depression of varying degrees of severity and alsoof neurotic or other psychic disturbances involving loss of initiativeand depressive disorders as well as of post-partum or postoperativedepressions, or of depression of different origin in a warm-bloodedanimal which comprises a therapeutically effective amount of a compoundof the formula I as defined in claim 1, in which Ar is unsubstituted orsubstituted one to three times by hydroxy, n represents the integer 1,alk represents an alkylene radical having from 2 to 4 carbon atoms, thenitrogen atom and the oxygen atom being separated from one another by 2carbon atoms, R₁ and R₂ represent hydrogen or lower alkyl, or apharmaceutically acceptable, non-toxic acid addition salt thereoftogether with a pharmaceutically acceptable excipient.
 35. A method forthe treatment of angina pectoris, cardiac arrhytmia as well asmyocardial insufficiency and for the reduction of blood-pressure in awarm-blooded animal which comprises the administration thereto of atherapeutically effective amount of a compound of formula I defined inclaim 1 or a pharmaceutically acceptable non-toxic acid addition saltthereof.
 36. A method for the treatment of reactive or endogenic statesof depression of varying degrees of severity and also of neurotic orother psychic disturbances involving loss of initiative and depressivedisorders as well as post-partum or postoperative depressions, ordepression of different origin in a warm-blooded animal which comprisesthe administration thereto of a therapeutically effective amount of acompound of the formula I as defined in claim 1, in which Ar isunsubstituted or substituted one to three times by hydroxy, n representsthe integer 1, alk represents an alkylene radical having from 2 to 4carbon atoms, the nitrogen atom and the oxygen atom being separated fromone another by 2 carbon atoms, R₁ and R₂ represent hydrogen or loweralkyl, or a pharmaceutically acceptable, non-toxic acid addition saltthereof.